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CHAPTER I 
INTRODUCTION AND REVIEW OF RELATED LITERATURE 
Research interest has recently developed for a 
group of chemical compounds which have immunomodulatory 
properties. These compounds exert anti-microbial actions 
which have been termed "prohost" (20) because, rather 
than being directly bactericidal or fungicidal, they 
either restore the host's deficient immune response or 
augment a normal response. Under specified conditions, 
these drugs could become highly important in treating 
immunodeficiency diseases, as well as viral, fungal, and 
bacterial infections. With the increasingly frequent 
development of single and multiple resistance to conven-
tional antibiotic therapy (4,6,10,21), immunopotentiators 
become increasingly more important therapeutic alterna-
tives. Also, in therapy for atopic individuals who 
experience undesirable side effects from traditional 
treatment (1,27,61), or in cases where adverse effects 
such as oto- or nephrotoxicity accompany the use of anti-
biotics (5,11), immunomodulators may provide successful 
treatment with fewer serious complications as a result 
of therapy. 
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Immunomodulatory substances consist of a wide 
variety of agents including micro-organisms and their 
subcellular fractions (mycobacteria, Corynebacterium 
parvuurn, LPS, zymosan), macromolecules such as nucleic 
acids or polynucleotides, small inorganic or organic 
molecules (silica, alum, fatty acids), or pharmacologic 
agents such as levamisole (1,2,3,5 tetrahydro-6-phenyl-
amidazo (2,1-S)-thiazol, monohydrochloride). These agents 
effect their actions in a number of ways: by prolonging 
antigen release, by recruitment of macrophages and lympho-
cytes, by stimulating proliferation and differentiation 
of immunologically competent cells or by the enhancement 
of cellularly mediated immune responses (64). 
Since complex immune mechanisms are affected by 
such immunomodulation, it could be expected that specific 
drug regimens may be more effective when immune cells are 
most sensitive to regulation. This has been demonstrated 
to occur in levamisole therapy where pre-infection drug 
treatment was effective against a bacterial agent (12) 
while simultaneous or post-infection therapy was ineffec-
tive. In particular, synthetic, non-polymer pharmacologic 
agents have been found to enhance the cellular immune 
response. A principle action of these agents involves 
the potentiation of the thymus-derived T-lymphocytes and 
the proliferation and/or activation of the monocyte-
derived tissue macrophage (20). 
2 
3 
One such immunomodulatory agent is SM-1213 (1,2-0-
isopropylidene-3-0-3'-(N',N'-dimethylamino-n-propyl)-D-
glucofuranose), a synthetic, substituted monosaccharide. 
The possible enhancement of host defenses by such a drug 
during active infection has prompted a careful examination 
of the in vitro and in vivo effects of this substance. 
Recent studies have elucidated the anti-viral or 
immunomodulatory properties of SM-1213 in rhinovirus (15, 
16), influenza and vaccinia viruses (17), and in herpes 
simplex virus infections in mice (39) and hamsters (18). 
Oral SM-1213 therapy has been demonstrated to delay death 
in Bl6 melanoma-bearing C57BL mice, as well as enhance 
delayed-type immune responses in Ha/ICR mice challenged 
with human type 0 red blood cells (38). In addition, 
SM-1213 has been shown to significantly increase intra-
cellular killing of bacteria (20) in studies concerning 
infection of a macrophage monolayer with Listeria mono-
cytogenes. No studies, however, have examined the effects 
of SM-1213 upon in vitro or in vivo fungal infection. 
Candida albicans is a fungus commonly found as part 
of the normal flora of many mammals, including man. It is 
considered an opportunistic fungus, since individuals who 
carry the organism do not display symptoms of infection 
unless injury or metabolic disorders reduce resistance 
to microbial invasion. Diabetes, indwelling catheters, 
and broad-spectrum antibiotic or immunosuppressive therapy 
4 
are all factors which favor the development of candidiasis. 
In addition, patients with various neoplasms, immunologi-
cal defects, or serious burns are highly susceptible to 
candidal infection (48). 
The wide range of factors contributing to suscep-
tibility to candidiasis, the poor and even damaging chemo-
therapy available, and the increased incidence of systemic 
disease (22) have made candidiasis a serious clinical 
problem. Therefore, studies of the causative organism 
were undertaken to examine the mechanisms of pathogenesis 
and immunity in candidiasis and the effects of SM-1213 
therapy on host defense. 
A. In Vitro Studies 
Several researchers have examined the ability of 
polymorphonuclear leukocytes (PMN) or macrophages to 
phagocytize and kill intracellular Candida albicans (2, 
36,60,63). In general, the PMN leukocyte has been demon-
strated to be more efficient in destroying Candida than 
the macrophage (2). 
Stanley and Hurley (60) observed that cultured 
mouse peritoneal macrophages were destroyed by the elon-
gation of candidal germ tubes and that escaping Candida 
survived ingestion. In addition, Lauria and Brayton (37) 
suggested that the pathogenicity of various strains of 
Candida albicans in mice is roughly correlated to the 
ability of Candida to form germ tubes and survive ingestion 
by leukocytes derived from human blood. These studies 
demonstrate the invasiveness of Candida to be related to 
the hyphal rather than to the yeast form of this micro-
organism. 
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Lehrer and Cline (36), however, have shown that a 
significant fraction of Candida phagocytized by PMN's in 
vitro are destroyed. Arai et al (2) also found the guinea 
pig peritoneal neutrophil capable of killing intracellular 
Candida in the presence of normal serum. Rabbit alveolar 
macrophages, on the other hand, whether in the presence of 
normal or immune serum, showed no Candida dead after one 
hour of incubation. No significant improvement of candi-
dacidal activity was observed when macrophages derived 
from immune or normal rabbits were exposed to immune serum, 
but an enhancement of phagocytic ability of these cells 
was evident. It was suggested that immune serum enhanced 
opsonization. However, Venkataraman et al (63), working 
with immune rabbit neutrophils, demonstrated no significant 
enhancement of phagocytosis, but rather an enhancement of 
candidacidal properties in combination with immune serum. 
Studies were therefore conducted in our laboratory 
to determine whether glycogen induced guinea pig peri-
toneal neutrophils and paraffin oil induced peritoneal 
macrophages could inhibit intracellular Candida in vitro 
with or without the addition of whole, normal guinea pig 
serum. 
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B. In Vivo Studies 
1. Intravenous Inoculations 
Conventional therapy for a systemic candidal in-
fection involves the use of a polyene antifungal agent 
such as amphotericin B. While being relatively effective 
in the treatment of such infections, amphotericin B has 
concomitant deleterious side effects, particularly renal 
damage (62). Since the kidney has also been demonstrated 
to be a primary organ damaged in systemic candidiasis (26, 
37,51,66), treatment of these patients with amphotericin 
B may compound the problem. In addition, individuals 
receiving immunosuppressive cortisone therapy often be-
come infected with Candida (13) and are subsequently 
treated with amphotericin B; recent evidence indicates 
that amphotericin B can be synergistically nephrotoxic 
in mice receiving cortisone therapy (30). 
Unlike amphotericin B, SM-1213 is a drug of low 
toxicity. The acute oral LDso of SM-1213 in mice (17), 
rats, and rhesus monkeys has been determined to be greater 
than 10 g/kg, or greater than 10 4 the usual therapeutic 
dose. In tissue culture studies, anti-viral and anti-
bacterial effects were demonstrated while toxicity to 
tissue culture cells was not evident at SM-1213 concen-
trations 1000 times higher than the effective dosage 
(17,20). 
In addition, unlike other immunomodulatory sub-
stances (12), 8~1-1213 does not require administration 
prior to infection (15,17,39). This aspect of SM-1213 
treatment could therefore prove useful in the therapy of 
disease states upon the appearance of symptoms (38). 
Therefore, if SM-1213 could be proven to be effective 
against a systemic candidal infection, it might provide 
a viable alternative to classical polyene antibiotic 
therapy. 
The pathogenesis of systemic candidal infection 
has been examined by several researchers; the kidney has 
been demonstrated to be a primary organ damaged by such 
infection. 
Hurley and Winner (26) described an acute and a 
chronic type of kidney involvement in Swiss mice infected 
intravenously with 1.5 X 10 4 to 4 X 10 6 candidal cells. 
Doses of 2 X 10 6 or more candidal cells per mouse caused 
animals to develop acute diseases and to succumb within 
one to ten days with histologically distinct lesions in 
the heart, brain, and kidneys. Chronic kidney disease 
occurred in mice dying in six to sixty days with lesions 
confined to the kidneys. 
In a similar study, Winbald (66) also showed that 
the kidney was an organ of major involvement. In mice 
infected with 8 X 10 4 Candida cells intravenously, his-
tology and scanning electron microscopy of the infected 
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kidneys demonstrated two types of involvement: acute 
(occurring within ten days of challenge) and chronic 
(occurring in those mice surviving longer than ten days 
post-infection) . 
Studies conducted by Rogers and Balish (50) on 
clearance of Candida from liver, lungs, kidneys, and 
spleens of male Swiss-Webster mice infected with various 
doses of Candida intravenously have shown that 60-120 
minutes after injection, the kidney, on a weight basis, 
was the most efficient organ for clearing Candida from 
the bloodstream. The kidneys became chronically infected 
17-24 days post-challenge with 1-3 X 10 4 viable units of 
Candida injected. Increasing numbers of Candida were 
found in the kidneys and, by day 24 post-infection, the 
number of viable units was as high as 1 X 10 6 per two 
kidneys. 
8 
Louria and Brayton (37) studied Swiss mice infected 
intravenously with various strains and inocula of Candida. 
Tissue homogenates were performed on kidney, spleen, 
liver, heart, brain, and lung tissues after intravenous 
challenge with 1 X 10 5 Candida cells of the PR strain. 
Progressive infection occurred only in the kidneys by 
day 7 post-infection. Populations in brain, heart, liver, 
spleen, and lung samples remained unchanged or fell by 
day 7, while that of the kidney increased. The authors 
suggested such an increase was related to a four hour 
9 
delay in mobilization of neutrophils to this organ and 
that, once Candida were able to germinate within the kidney 
tubule lumens, they were able to evade the host's inflamma-
tory response. 
2. Intramuscular Inoculations 
Mice injected intravenously with Candida albicans 
frequently succumb to infection within two weeks, which 
hinders the study of the course of an immune response. 
By using a model developed by Selbie and O'Grady (57) and 
modified by Pearsall and Lagunoff (44), it became possible 
to study the mechanisms of candidal pathogenesis and 
immunity in mice under the influence of drug therapy. 
Selbie and O'Grady (57) developed a model whereby 
mice were injected intramuscularly in the thigh so as to 
produce a measurable tuberculous lesion. Pearsall and 
Lagunoff (44) used such a model to examine experimental 
candidiasis in mice. An inoculum of 5 X 10 8 Candida cells 
was injected into the thigh muscle of C57BL/Ks mice and 
the development of candidal abscesses was monitored by 
periodic measurement of the infected leg with the aid of 
a caliper. Histological examination revealed a predom-
inantly granulocytic infiltrate of cells. Lesions were 
self-limiting within four to six weeks post-infection. 
Immunity to abscess formation could be passively 
transferred by the use of immune serum, but not by the 
administration of lymphoid cells obtained from convalescing 
mice ( 43) . 
Secondary leg inoculations of Candida into the 
uninfected contralateral leg of recovered mice were also 
conducted by Pearsall and Lagunoff (43). Such inocula-
tions were used by Pearsall and Lagunoff to determine the 
acquisition of immunity to abscess formation following an 
initial infection. 
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While Pearsall and Lagunoff (44) examined the 
histology of the leg lesions, no culturing of the abscesses 
or visceral organs was conducted. 
C. Purpose of the Present Work 
The purpose of this thesis is to examine the pos-
sible enhancement of host defenses by SM-1213 during an 
infection produced by experimental injection of Candida 
albicans. Initially, in order to determine whether or not 
there is a direct fungicidal or fungistatic activity asso-
ciated with SM-1213 treatment, an examination of the effect 
of SM-1213 concentration on the growth of the yeast and 
hyphal forms of Candida albicans will be undertaken. In 
addition, an examination of the effect of SM-1213 concen-
tration upon leukocytes infected in vitro with C. albicans 
will be discussed. In particular, SM-1213 treatment will 
be investigated for its effect on the ability of peritoneal 
exudate cells in tissue culture to inhibit intracellular 
germ tube elongation and to reduce candidal viability. 
The effect of whole, normal guinea pig serum on germ tube 
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elongation and candidal viability within phagocytic leuko-
cytes in the presence and absence of SM-1213 will also be 
examined. 
In vivo, studies will be conducted to examine the 
effects of oral SM-1213 drug therapy upon systemic infec-
tion in mice injected intravenously with C. albicans. 
Since host defense mechanisms evolve during the interval 
following the initiation of infection, and since immune-
modulatory substances may prove most effective when host 
defense mechanisms are sensitive to regulation (12), 
various regimens of drug treatment will be tested. In 
addition, since the kidney is a primary organ in the path-
ogenesis of candidiasis (26,66), tissue homogenizations 
of kidneys from intravenously infected mice will be per-
formed to assess renal involvement in control and drug 
treated mice. 
The effects of SM-1213 treatment on the course of 
leg lesion development in intramuscularly infected mice 
will also be investigated. Leg lesion development will 
be monitored periodically with the aid of adjustable 
calipers and leg swelling will be used as an indicator of 
the pathogenesis of candidal disease. Recovered mice will 
be reinoculated in the contralateral leg to assess the 
effect of SM-1213 on lesion development during a second 
infection when drug is administered during initial infec-
tion only. Also, leg lesions will be cultured or homo-
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genized to detect the presence of C. albicans and kidneys 
and/or spleens of intramuscularly infected mice will be 
examined for the metastatic spread of fungus. It is hypo-
thesized that SM-1213, via its irnrnunomodulatory properties, 
will promote the fungistatic or fungicidal capabilities of 
leukocytes in vitro and will promote an enhanced host 
defense in vivo against experimentally induced infections 
of Candida albicans. 
CHAPTER II 
MATERIALS AND METHODS 
A. Experimental Drug 
SM-1213 (1,2-0-isopropylidene-3-0-3'-(N',N'-di-
methylamino-n-propyl)-D-glucofuranose, monohydrochloride) 
was supplied by Dr. Paul Gordon, Greenwich Pharmaceuticals, 
Inc., Greenwich, CT. and Department of Microbiology, 
Loyola University, Stritch School of Medicine, Maywood, IL. 
The chemical structure of the drug is represented in 
Figure 1. SM-1213, lot #13/24-31, hydrated from the 
powdered form with distilled water, was stored at -20°C 
in 5 ml stock solutions (50 mg/100 ml) and diluted as 
needed. 
B. Micro-organism 
Candida albicans originally isolated from a human 
patient was kindly supplied by Dr. T. Hashimoto of this 
department. Permanent stocks were lyophilized in Sabour-
aud's dextrose broth (Difco) and rehydrated as needed. 
Working stocks were kept on Sabouraud's dextrose agar 
(Difco) slants at room temperature and at 4°C and trans-
ferred at monthly intervals. 
This strain showed typical features of Candida 
albicans when tested in a Uni-Yeast-Tek diagnostic system 
13 
14 
Figure 1. The chemical structure of SM-1213 (1,2-0-
isopropylidene-3-0-3'-(N', N'-dimethylamino-n-propyl)-D-glu-
cofuranose, monohydrochloride). 
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(Corning Medical Microbiology, Roslyn, NY). Assimilation 
of sucrose and maltose with latent assimilation of tre-
halose and soluble starch and lack of lactose, raffinose, 
and cellobiose utilization as well as negative urea and 
nitrate tests were identifying characteristics. In addi-
tion, characteristic germ tube formation in the presence 
of serum, characteristic filamentous growth on EMB agar, 
and typical chlamydospore formation on corn meal-tween 
agar were confirmatory. 
Cultures used for injection were grown for 24 to 
72 hours at 37°C on Sabouraud's dextrose agar (SDA) or in 
Sabouraud's dextrose broth (SDB) to which 50 ~g gentamicin/ 
ml (Garamycin, Schering Pharmaceutical Corp., P.R.) had 
been added to retard bacterial growth. 
Final suspensions of Candida to be used for injec-
tion were made in sterile Na-K phosphate buffered saline 
(PBS, pH 7.3, % w/v in distilled water: NaCl 0.8, KCl 0.02, 
KH 2 P0 4 0.012, and Na 2 HP0 4 0.091). Candida were quantified 
prior to infection in a hemocytometer (Bright-Line, Amer-
ican Optical Co.) and serially diluted and plated on SDA 
for the determination of colony forming units. 
Day 1 has been designated as the day of infection 
in all of the following experiments. 
C. Experimental Animals 
Intravenous inoculations were carried out in male, 
randomly-bred, Ha/ICR mice (Sprague-Dawley, division of 
Mogul Corp., Madison, Wise.). Several strains of mice 
were tested for use in leg inoculation studies (Ha/ICR, 
C3H, Balb/c, and CBA/J). The CBA/J strain of mouse was 
determined to be most suitable for these studies for 
reasons which will be detailed later. CBA/J mice were 
numbered by ear punch and randomized for each experiment. 
Ha/ICR mice were numbered with 0.1% w/v picric acid-
ethanol dye and randomized for each experiment. Mice 
were primarily 4 to 6 week old males, weighing 20 to 25 
grams at the time of experimental initiation. 
Mice were fed (Purina Rat Chow #5012) and watered 
ad libitum. Animals were housed at this laboratory's 
isolation facility (Building 188) in plastic cages in 
groups of 5 to 10 per cage. Twelve hour diurnal rhythms 
were maintained with automatically timed lighting. Tem-
peratures were controlled to comfortably maintain the 
animals at 22-24°C. 
Male guinea pigs, Hartley strain, weighing approx-
imately 500 grams, were housed on the second floor of the 
Stritch School of Medicine in metal cages in groups of 
three. The guinea pigs were fed (Purina Guinea Pig Chow) 
and watered ad libitum. Guinea pigs were used for peri-
toneal exudate cell harvests, since sufficient numbers of 
leukocytes could be obtained from one animal for each 
experiment. 
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D. Drug Administration 
Drug was administered ad libitum in the drinking 
water of animals receiving therapy. Water consumption of 
drug treated animals was similar to control animals re-
ceiving water without an additive. Drug concentrations 
were prepared so as to allow the desired consumption over 
each 24-hour interval based on the observed drinking 
habits of the experimental animals. Thus, for normal 
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mice early in infection, 4 ml of water was consumed per 
day per mouse. Alternatively, drug was administered by 
gavage. Gavage doses were administered according to the 
average cage weight and were given as ~g/kg/day. Stain-
less steel gavage tubes (Popper and Sons, Inc., New Hyde 
Park, NY) were placed on 1 ml tuberculin syringes (Becton-
Dickinson and Co., NJ) and drug was thereby given orally 
by placement of the tube into the esophagus. 
E. Statistical Analysis 
In mortality studies, tissue homogenization studies, 
and viability studies, the x2 analysis was used; for germ 
tube elongation averages and average animal weight and 
abscess sizes, the Student's t test was utilized. The 
Pearson's r was used to determine correlations. Averages 
were represented plus or minus (±) the standard error of 
the mean. P values were considered significant when they 
were less than 0.05. 
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F. In Vitro Studies 
1. Methods for Determining the Effects of SM-1213 on the 
Growth of Candida albicans 
In order to determine whether SM-1213 had direct 
inhibitory effects on the growth of Candida, 100 ml of 
Sabouraud's dextrose broth (SDB) in 500 ml side-arm Erlen-
meyer flasks were inoculated with 1 X 10 5 Candida cells. 
Candida had been grown for 24 hours on SDA at 37°C prior 
to inoculation. The increase in turbidity in each of 
five flasks with different concentrations of SM-1213 were 
monitored. Concentrations of SM-1213 tested were: 0 
(Control), 1.0, 0.1, 0.01, and 0.001 ~g/ml. Also, a con-
trol blank (no drug, no Candida) was examined. Hourly 
turbiometric readings were taken at 660 nm on a Bausch 
and Lomb Spectronic 70 spectrophotometer over a period of 
ten hours. Since greater than 98% of Candida grew in the 
yeast form in SDB, such readings demonstrated what effect, 
if any, SM-1213 had on this morphologic form of Candida. 
The normal growth of this particular strain of Candida 
albicans in SDB was also determined from this data. 
To determine whether SM-1213 had a direct effect 
upon the hyphal form of Candida, 250 ml flasks containing 
50 ml of HI-W05/BA2ooo tissue culture medium with the 
above concentrations of SM-1213 were inoculated with 10 5 
Candida cells and incubated for 24 hours on a rotary shaker 
at 37°C. The growth was determined in each of these 
flasks by dry weight analysis. Dry weight determinations 
were made after Millipore filtration of the cultures. 
Three washes of the Candida were performed with distilled 
water while on the filtration system, followed by drying 
of the filters in a Stabil-Therm oven (Model #OV-12) at 
60°C for 48 hours. 
2. Methods for Peritoneal Cell Harvest, Infection add 
Tissue Culture 
One white guinea pig (Hartley strain, male, 500 g) 
was used in each of the in vitro experiments as a source 
of peritoneal exudate cells. Either 20 ml of paraffin 
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oil (mineral oil) or glycogen (0.1% w/v in Earle's bal-
anced salt solution) was used as an inducing agent. 
Harvesting procedures were identical for both types of 
inducing agents except that the paraffin oil was injected 
into the peritoneal cavity 72 hours prior to animal sac-
rifice while the glycogen was injected 24 hours prior to 
sacrifice. The abdomen of the guinea pig was shaved with 
an electric shaver (Oster) and cleansed with 70% isopropyl 
alcohol (Alco-Wipes, Will Ross, Inc., Milwaukee, WI) prior 
to injection of the inducing agent. 
On the day of sacrifice, peritoneal cells were 
harvested from the guinea pig by five serial washes of 
20 ml volumes of heparinized Eagle's basal medium (BME) 
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containing 50 ~g gentamicin/ml. Five units of heparin/ml 
was included in the medium to inhibit aggregation of exu-
date cells. A 20 ml plastic syringe and 19 gauge needle 
was used to deliver the BME into the peritoneum for each 
wash. Cell harvests were facilitated by a 5 em longitu-
dinal incision in the abdominal wall to allow access to 
the peritoneum. A 5 ml polystyrene disposable pipet 
(Scientific Products, Division of American Hospital Supply) 
could then be used to collect the wash fluid from the 
cavity. Polystyrene equipment was used to lessen the ad-
herence and subsequent loss of peritoneal cells during 
harvesting procedures. The washes were delivered into 
sterile, 40 ml screw-cap plastic centrifuge tubes and the 
cells were pelleted by centrifugation at 250 X G for 5 
minutes (20°C) in an International PR-6 centrifuge. The 
pellet was resuspended and washed three times in HI-W0 5 / 
BA 2000 serum-free medium (International Scientific). 
After washing, the cells were counted in a hemo-
cytometer (Bright-Line, American Optical). A total leuko-
cyte count was made and a differential count was then 
performed on Wright-Giemsa (Harleco, Division of American 
Hospital Supply) stained smears. 
Total harvests ranged from 5.8 X 10 7 cells from 
paraffin oil induction (65% macrophages) to 1.1 X 10 7 
cells from glycogen induction (54% polymorphonuclear cells; 
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remainder rnacrophages, rnonocytes, and lymphocytes). Cells 
were then seeded onto 60 rnrn plastic tissue culture Petri 
plates containing two 2.2 ern square glass cover slips (#1 
thickness) . It was found that the most workable number 
of cells was 2 X 10 6 per Petri plate. These cells were 
then incubated in HI-vv0 5 /BA2ooo medium with or without the 
addition of SM-1213 for two hours at 37°C, 5% C02 atmos-
phere, to allow attachment of the cells to the cover slips. 
Concentrations of SM-1213 tested were 0.1, 0.01, 0.001, 
and 0.0 (control) ~g/rnl. 
In cell cultures containing 2 X 10 6 peritoneal 
cells per plate, 2 to 4 X 10 5 Candida cells were inocula-
ted into the culture medium directly following the addi-
tion of peritoneal cells. After two hours, non-adherent 
cells were removed by washing once with HI-W0 5 /BA2000 
medium and appropriate medium (with or without SM-1213) 
was replaced for those samples requiring further incuba-
tion. In this way, any extracellular Candida was removed 
after the initial two hours of incubation by the medium 
wash described above. A Candida to peritoneal cell ratio 
of 1:5 to 1:10 permitted ideal measurements, since only 
one Candida would be contained in any one peritoneal cell. 
In studies employing serum, whole normal guinea pig serum 
obtained from cardiac puncture and stored frozen at -20°C 
was added to each sample to a final concentration of 2% 
v/v. Serum was added to the cultures following the addi-
tion of cells. 
Candida albicans was grown on Sabouraud's dextrose 
agar for 24 hours at 37°C. Under these conditions, 
greater than 95% of the Candida cells were in the yeast 
phase. Suspensions of Candida were made in phosphate 
buffered saline (PBS, pH 7.3). A Klett colorimeter 
reading (Filter #66) of 100 was determined by colony 
count enumeration to be equivalent to 1 X 10 7 Candida 
cells/ml. 
a. Determination of Candidal Germ Tube Elongation 
At intervals of 2, 4, and 6 hours, one cover slip 
was removed from the Petri plate and placed in a staining 
dish containing 95% methanol for 5 minutes. Such treat-
ment caused the cells to become fixed and allowed for 
microscopic examination. Upon removal from the methanol 
bath, the cover slip was air dried and inverted onto a 
drop of distilled water on a glass microscope slide. The 
peritoneal cells on the cover slip were then examined by 
phase contrast microscopy at lOOOX for intracellular germ 
tube elongation. The germ tube lengths of Candida con-
tained in 50 peritoneal cells were determined through the 
use of a micrometer in the eyepiece of the microscope. 
Intracellular germ tube elongation was monitored at the 
2, 4, and 6 hour intervals in this manner. 
23 
b. Determination of Candidal Viability 
The second, remaining cover slip was removed from 
the Petri plate with forceps and rinsed in successive 
baths of PBS and SDB. Such baths were instituted to 
remove any residual tissue culture medium from the cover 
slip. Candida develop hyphae in tissue culture medium 
and the yeast form, which develops on SDA, was required 
for this section of the assay. (Viability of Candida was 
determined by their ability to grow out of peritoneal 
cells via hyphae and form colonies of yeast on SDA. 
Morphology was therefore highly important in this assay.) 
I 
Washed cover slips were then drained by touching one 
corner of the cover slip to a piece of filter paper. The 
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cover slip was then inverted onto a Petri plate containing 
1 a thin layer (3 mm) of SDA and incubated for 2~ hours at 
37°C (normal atmosphere) . If not properly drained, air 
would be occluded between the cover slip and the agar 
and hyphae would develop. After incubation, the Petri 
plates were refrigerated overnight at 4°C and examined 
microscopically at lOOOX the next day for Candida colony 
formation. Four adjacent yeast cells were designated as 
one colony unit. The percentage of viable Candida cells 
could then be determined by counting 100 peritoneal cells 
~hich contained Candida: 
Number of Candida forming colonies % 
Number of Candida X 100 = 
Number of Candida + unable to form 
forming colonies colonies 
G. In Vivo Studies 
1. Intravenous Inoculations 
Viable 
cells 
The object of this series of studies was to deter-
mine the effects of SM-1213 treatment on the survival 
rate of mice with experimentally induced systemic infec-
tions of Candida albicans. In particular, the effects of 
various regimens of drug therapy were investigated. 
a. Computation of the 50% Lethal Dose (LD 50 ) 
The method of Reed and Muench (47) was used to 
determine the LDso for the strain of Candida albicans 
used in the following experiments. Candida doses used 
for these calculations were 10 8 , 1.5 X 10 7 , 10 6 , and 10 5 
per animal injected intravenously into the left lateral 
tail vein of male, Ha/ICR mice; a 26-gauge needle and a 
1 ml tuberculin syringe were utilized. Candida were sus-
pended in sterile PBS and 0.1 ml volumes were injected. 
b. Methods for Mouse Mortality Studies 
Yeast cell suspensions of Candida albicans were 
made in PBS and counted in a hemocytometer. Candida were 
grown for 48 hours on SDA at 37°C. Viability of candidal 
suspensions was determined by plating serial dilutions 
by the spread plate method and counting colony formation 
48 hours later. 
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Male, Ha/ICR mice were injected with 2 X 10 5 
Candida cells in the lateral tail vein with a 26-gauge 
needle and 1 ml tuberculin syringe; volumes injected were 
0.1 ml per mouse. 
SM-1213 was administered ad libitum in the drink-
ing water of test animals for various 24-hour intervals 
only. A dosage of 80 ~g/kg/day was administered for 24 
hours only either beginning on the day of infection 
(immediately following infection and designated as day 
1-2 treatment), or beginning one, two, or three days 
following infection (designated as day 2-3, day 3-4, and 
day 4-5 treatment, respectively). 
2. Intramuscular Inoculations 
In primary leg inoculations, male, CBA/J mice were 
injected into the right lateral calf muscle with either 
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7 X 10 6 , 1.25 X 10 7 , or 1.25 X 10 8 Candida cells per 
mouse, depending upon experimental design. The left leg 
served as a control for daily measurements, as did unin-
fected control animals injected with PBS only in the right 
leg. The diameter (lateral to medial) of the uninfected 
left leg of each mouse was subtracted from the diameter 
of the infected right leg to determine the size of the 
abscess produced. Such methods were undertaken to allow 
for any increases in leg diameter due to growth of the 
animal which would occur bilaterally. Corrections for 
original differences between the right and left leg were 
made by measuring both legs before infection, determining 
the difference, and subtracting this original difference 
from the post-infection difference for each animal for 
each measurement day. Such corrections did not signifi-
cantly alter the average abscess size of any experimental 
group; however, corrections were made to determine the 
more precise abscess size for each animal before averages 
were calculated. The phrase ''abscess size" has been used 
interchangeably with the phrase ''leg swelling." The 
latter is the more correct expression of leg measurement 
data. 
Injections were made with a 27-gauge needle and 1 
ml tuberculin syringe. Leg swelling was measured mechan-
ically in mm using a Schnelltaster numerical dial caliper 
(H. Kroplein, Hassen, W. Germany). Care was taken to 
extend the leg thoroughly when measurements were taken. 
Secondary leg inoculations in mice which had re-
covered from a primary leg infection were performed on 
the uninfected contralateral leg with 1 X 10 5 Candida 
cells intramuscularly. No further administration of drug 
was used beyond that given during the primary infection. 
Re-inoculation was performed on day 57 of the primary 
infection; therefore, the long-term effects of SM-1213 
treatment given during the initial infection were exam-
ined during a second infection. 
27 
a. Tissue Homogenization Techniques 
In order to obtain a quantitative measurement of 
candidal infection, tissue homogenization studies were 
undertaken. Spleens, abscesses, and/or kidneys were 
removed aseptically and placed into sterile vials con-
taining 2 to 5 ml of PBS. Tissues were homogenized in 
this solution with Duall 24 ground glass tissue homogen-
izer tubes and pestles (Kontes Glass Co.) A Tri-R Stir-R 
(50 to 1100 variable rpm, model K-43) motor was used at 
setting #7. After homogenization, tubes and pestles were 
rinsed with 3 to 5 ml of PBS whichwere then added to the 
tissue homogenate. Each spleen, abscess, and each pair 
of kidneys was homogenized separately. Abscesses were 
obtained by excising the abscess and all surrounding 
muscle tissue located between the knee and ankle joint 
with sterile surgical scissors. 
Quantitation of viable Candida was obtained by 
serial dilution of the tissue homogenates and spread 
plate enumeration. Three dilutions of each sample were 
plated in duplicate (10- 1 , 10- 3 , and 10- 5 ) and colony 
counts were performed on 48-hour cultures incubated at 
37°C. 
b. Culturing Techniques 
At the time of sacrifice, animals were killed by 
cervical dislocation and the right leg was skinned and 
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removed aseptically by cutting with surgical scissors 
transversely through the femur and the ankle. This por-
tion of the leg, containing the abscess, was placed into 
25 ml sterile, cotton-plugged Erlenmeyer flasks containing 
10 ml of SDB + gentamicin (Gm) . The specimen was minced 
50 times with surgical scissors which had been flame 
sterilized with ethanol. Flasks were then placed in a 
shaking water bath incubator (Warner-Chilcott Laboratories, 
Morris Plains, NJ) at 37°C for 24 hours. Colony count 
enumerations were carried out on serial dilutions of the 
tissue suspension plated out on SDA and incubated for 48 
hours at 37°C. Similarly, each pair of kidneys and each 
spleen was aseptically removed and cultured in the same 
manner following mincing. Such a technique was developed 
so that qualitative differences could be determined be-
tween samples. This was particularly importantin detecting 
small quantities of micro-organisms which may not have been 
detected using classical tissue homogenization techniques. 
c. Weight Gain Determinations 
In weight gain studies, correction for abscess 
weight was determined by subtracting the weight of a 
sphere from the animal weight. The volume of the sphere 
was determined by using one-half the abscess size as the 
radius in the equation V = jnr 3 • The density was desig-
nated as approximately equal to 1 g/ml and the mass could 
thereby be determined mathematically (mass = density X 
volume) and subtracted from the animal weight. 
30 
CHAPTER III 
RESULTS 
A. In Vitro Studies 
1. Effects of SM-1213 on the Growth of Candida albicans 
As shown in Tables 1 and 2, SM-1213 had no direct 
fungicidal or fungistatic activity against Candida when 
tested in Sabouraud's dextrose broth (yeast form of 
Candida) or HI-WOs/BAzooo tissue culture medium (hyphal 
form of Candida). Turbidity was virtually identical in 
all samples tested regardless of drug concentration (see 
Table 1) . The higher turbidometric reading obtained for 
the control sample at the 5 hour interval was attributed 
to a procedural artifact resulting from insufficient 
shaking of the sample flask. Thorough shaking of the 
sample flask for subsequent readings resulted in a more 
even distribution of Candida in the SDB and the elimina-
tion of aberrant readings. 
Dry weights of Candida grown in tissue culture 
medium for 24 hours with and without SM-1213 present were 
also very similar, as were the pH readings of the culture 
supernatants (see Table 2). The pH of the culture super-
natant was used as an indication of change in acidity of 
the medium due to candidal growth. 
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Table l. Effect of SM-1213 on the growth of Candida albicans 
in Sabouraud's dextrose broth (SDB)a: 
Incubation Growth of c.albicans at 37°C.b 
time (hrs) SM-1213 concentration ' SDB ( JJ g7m1) 1n 
0 1.0 0.1 0.01 0.001 
1 0.050 0.045 0.035 0.030 0.047 
2 0.056 0.038 0.075 0.048 0.060 
3 0.095 0.116 0.129 0.101 0.102 
4 0.221 0.192 0.167 0.201 0.228 
5 0.525 0.303 0.320 0.283 0.333 
6 0.300 0.309 0.300 0.300 0.308 
7 0.450 0.460 0.460 0.460 0.480 
8 0.610 0.620 0.610 0.610 0.620 
9 0.740 0.750 0.740 0.740 0.750 
9.5 0.840 0.850 0.850 0.840 0.850 
10 0.940 0.950 0.940 0.950 0. 950 
a)lOO ml of SDB was inoculated with 1 X 105 c.a1bicans in 
each of five 500 ml side-arm Erlenmeyer flasks containing 
the specified concentration of SM-1213 at the time of inoc-
ulation. 
b)Growth of C.albicans was monitored by the increase in turb-
idity of candidal cultures with time. Spectrophotometric 
readings were taken at each time interval at 660 nm. 
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Table 2. Effect of SM-1213 on the growth of Candida albicans 
in tissue culture mediuma 
SM-1213 
concentration 
in TC medium 
( J.lg/ml) 
0 
1.0 
0.1 
0.01 
0.001 
pH of TCb 
medium 
7.35 
7.10 
7.24 
7.35 
7.35 
Dry weightc 
(grams) 
0.0297 
0.0291 
0.0307 
0.0311 
0.0311 
a)50 ml of HI-W05/BA2000 tissue culture medium was inoculated 
with 1 X 105 C.albicans in each of five 250 ml Erlenmeyer 
flasks and incubated for 24 hours on a rotary shaker at 
37°C. 
b)pH of supernatant TC medium in which c.albicans was grown. 
c)Dry weight determinations of candidal-growth from (a) above 
after 24 hours incubation at 37°C in TC medium. Cultures 
were Millipore filtered, washed, and dried at 60°C for 48 
hours. 
2. Tissue Culture Studies 
a. Effect of SM-1213 on Germ Tube Elongation of Phago-
cytized Candida albicans in the Absence of Serum 
In the first experiment employing paraffin oil 
induced guinea pig peritoneal cells, two drug levels and 
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a control group were tested. As demonstrated in Figure 2, 
the average germ tube lengths were nearly identical in 
the control group and the drug treated groups until the 
6-hour sampling time. At this point, the average germ 
tube length in the control group was significantly higher 
than in the SM-1213 treated samples. 
The apparent lag in time before the divergence 
between the control and drug groups would seem to indi-
cate that there is a mechanism by which SM-1213 induces 
a change in the ability of the peritoneal exudate cells 
to inhibit the growth of intracellular Candida, but that 
there is an interval before the peritoneal cells are 
activated or before the activation can mediate an effect. 
The lower drug concentration of SM-1213 (0.001 
~g/ml) inhibited germ tube elongation more efficiently 
than did the higher drug concentration (0.01 ~g/ml) after 
6 hours of incubation, while both drug treated groups 
were significantly lower than the control. 
Drug treated groups also showed the lowest intra-
cellular viability (see Figure 3). The differences in 
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Figure 2. Effect of SM-1213 on germ tube elongation 
of phagocytized Candida albicans in mineral oil induced ex-
udate cells in the absence of serum. 
Phagocytic leukocytes were induced by i.p. injection 
of mineral oil into a male, Hartley strain guinea pig 72 
hours prior to cell harvest. Germ tube lengths were measured 
microscopically at lOOOX via a micrometer in the microscope 
eyepiece. Each point represents the average germ tube length 
(±S.E.) of 50 intracellular Candida cells measured at the 
designated time interval. (e) Control; (•) 0.01 ~g SM-1213/ml 
TC medium; (•) 0.001 ~g SM-1213/ml TC medium. 
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Figure 3. Effect of SM-1213 on the viability of 
phagocytized Candida albicans in mineral oil induced exudate 
cells in the absence of serum. 
Each data point represents the percentage of viable 
Candida cells in 100 leukocytes containing fungus. 
% Viability = # of Candida forming colonies X 100; #of Candida +#of Cand1da unable 
forming colonies to form colonies 
a colony was designated as four adjacent c.albicans yeast 
cells formed on Sabouraud's dextrose agar-after two and one-
half hours of secondary incubation at 37°C. {e) Control; 
{A) 0.01 ~g SM-1213/ml TC medium during initial incubation; 
{•) 0.001 ~g SM-1213/ml TC medium during initial incubation. 
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viability, unlike germ tube length, were apparent after 
only 2 hours of incubation. Thus, exposure to SM-1213 
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for as little as 2 hours can mediate an effect on candidal 
viability. 
Since percent viability is a measure of the ability 
of candidal cells to emerge from within peritoneal cells 
and form colonies on SDA, germ tube lengths do not strict-
ly correlate with viability results during the first hours 
of incubation when germ tubes are wholly contained within 
leukocytes. Apparently, during the subsequent 2~ hours 
of incubation on SDA, germ tubes in the control sample 
were better able to escape from within the peritoneal 
cells and form colonies, even though their average length 
at the 2- and 4-hour intervals in tissue culture were 
comparable to drug treated groups. 
It was noted also that, after 6 hours of incuba-
tion in tissue culture followed by incubation on SDA, the 
control group formed massive colonies, which were greater 
in size as well as in number than the drug treated 
groups. This indicates that the drug may be implicated 
in the reduction of candidal division and multiplication 
upon agar after exiting peritoneal cells as a result of 
its effect on leukocytes while in tissue culture. The 
correlation between the average germ tube length and the 
percent viable cells was strong by the 6-hour interval of 
tissue culture, as will be discussed later. 
In an experiment where glycogen was used as an 
inducing agent, germ tube elongation was more greatly 
inhibited than in the paraffin oil induced experiment 
above (see Figure 4). The germ tube lengths in the 0.001 
~g/ml treatment group were significantly shorter than in 
the control. It was speculated that the hyphae were dis-
integrating rather than elongating due to the observed 
loss of cell envelope integrity in treated samples. 
All drug groups demonstrated shorter germ tube 
lengths than the control. Here, unlike the previous 
experiment which used paraffin oil induction, the differ-
ences in germ tube lengths were apparent after 4 hours 
of incubation time. 
The effects of SM-1213 on the percent viable cells 
in this study were also apparent. All drug treated 
groups showed lower viability than the control. The 
lowest concentration of drug (0.001 ~g/ml) showed the 
lowest Candida viability and was significantly different 
from the control (see Figure 5). 
b. Effect of SM-1213 on Germ Tube Elongation of Phago-
cytized Candida albicans in the Presence of Serum 
Once again, paraffin oil was used as an inducing 
agent in this study. However, whole, normal guinea pig 
serum was added to the tissue culture medium to determine 
what effect it might have on germ tube elongation and 
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Figure 4. Effect of SM-1213 on germ tube elongation 
of phagocytized C.albicans in glycogen induced exudate cells 
in the absence of serum. 
Phagocytic leukocytes were induced by i.p. injection 
of glycogen (0.1 % w/v in EBSS) into a male, Hartley strain 
guinea pig 24 hours prior to cell harvest. Germ tube lengths 
were measured microscopically at lOOOX via a micrometer in 
the microscope eyepiece. Each point represents the average 
germ tube length (±S.E.) of 50 intracellular Candida cells 
at the designated time interval. (e) Control; <+) 0.1 ~g SM-
1213/ml TC medium; (A) 0.01 ~g SM-1213/ml TC medium; and 
(T) 0.001 ~g SM-1213/ml TC medium. 
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Figure 5. Effect of SM-1213 on the viability of 
phagocytized Candida albicans in glycogen induced exudate 
cells in the absence of serum. 
Each point represents the percentage of viable 
Candida cells in 100 leukocytes containing fungus. Percent-
age viability was determined as in Figure 3. (e) Control; 
(+) 0.1 ~g SM-1213/ml TC medium during initial incubation; 
(A) 0.01 ~g SM-1213/ml TC medium during initial incubation; 
(•) 0.001 ~g SM-1213/ml TC medium during initial incubation. 
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candidal viability. In this study (see Figure 6), signif-
icant differences in average germ tube length were not 
observed. 
When compared to Figure 2, where paraffin oil was 
used but no serum was added, the overall average germ 
tube length of the control sample at the 6-hour interval 
was significantly less in the presence of serum. It would 
appear from this data that the addition of serum to the 
tissue culture fluid inhibits the rapid elongation ob-
served in the first serum-free experiment between the 
4- and 6-hour interval. Serum did not significantly 
reduce the average germ tube length of drug treated 
samples, although some reduction was apparent (see upper 
half of Table 3). It is speculated that SM-1213 may 
mimic an unknown serum factor which may stimulate peri-
toneal cells to inhibit germ tube elongation. 
Although no significant differences were noted in 
average germ tube length, the lowest dose of SM-1213 
(0.001 ~g/ml) was significantly effective in reducing 
Candida viability at the 6-hour interval (see Table 4). 
In addition to germ tube length and viability, 
the percentage of peritoneal exudate cells containing 
intracellular Candida was determined for each interval. 
This was calculated by counting 100 peritoneal cells in 
each test group. The percentage of these cells which 
contained Candida was then determined. 
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Figure 6. Effect of SM-1213 on germ tube elongation 
of phagocytized Candida albicans in mineral oil induced ex-
udate cells in the presence of serum. 
Procedures were identical to those described in Fig-
ure 2 except, in this case, 2% v/v whole, normal guinea pig 
serum was added to the incubation medium. Each point repre-
sents the average germ tube length (±S.E.) of 50 intracellu-
lar Candida cells at the designated time interval. (e) Con-
trol:(~) 0.1 ~g SM-1213/ml TC medium; (A) 0.01 ~g SM-1213/ml 
TC medium; (T) 0.001 ~g SM-1213/ml TC medium. 
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Table 3. Effect of SM-1213 on the germ tube length of Candida 
albicans in the presence or absence of serum 
SM-1213 
concentration 
( llg/ml) b 
Hineral oile 
0 
0.001 
0.01 
Glycogenf 
0 
0.001 
0.01 
a Average germ tube length (ll) 
Without serum With serumc 
52.68 ± 3.83g 27.94 ± 3.30 
27.68 ± 3.30* 20.82 ± 3.00 
39.28 ± 3.80* 32.82 ± 3.86 
9.34 ± 1.74 6.80 ± 1.58 
3.94 ± 0.72* 3.80 ± 0.91 
6.28 ± 1.31 3.12 ± 1.03* 
Significance 
leveld 
p < 0.001 
N.S. 
N.S. 
N.S. 
N.S. 
N.S. 
a)50 C.albicans cells contained within leukocytes were meas-
ured for germ tube length after 6 hours of incubation time 
in HI-W0 5/BA2000 tissue culture medium at 37°C, 5% C0 2 • 
Germ tube lengths were measured by the use of a micrometer 
in the eyepiece of a microscope at lOOOX. 
b)Incubation medium contained the specified concentration of 
SM-1213. 
c)Incubation medium contained 2% v/v whole, normal guinea 
pig serum. 
d)N.S. indicates P > 0.05 by Student's t test. 
e)Mineral oil was used as an inducing agent for leukocyte 
harvest; 20 ml was injected i.p. into a male, Hartley 
strain guinea pig 72 hours prior to cell harvest. 
f)Glycogen was used as an inducing agent; 20 ml of a 0.1% 
w/v solution of glycogen in Earle's balanced salt solution 
was injected as in (e) above except 24 hours prior to cell 
harvest. 
g)Average germ tube length in microns plus or minus the 
standard error of the mean (±S.E.); an asterisk (*) fol-
lowing the S .E. indicates a significant (P < 0. 05) differ-
ence in germ tube length between the drug treated and 
control sample by Student's t test. 
Data was compiled from four experiments. 
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Table 4. Effect of SM-1213 on the viability of phagocytized 
Candida albicans in mineral oil induced exudate 
cells 1n the presence of seruma 
SM-1213 Percentage viable C.albicansC 
concentration 
(llg/ml) b Incubation time (hours) d 
2 4 6 
0 N.D.e 74 79 
0.001 62 64 56*f 
0.01 70 72 74 
0.1 65 60 72 
a)Initial tissue culture incubation medium contained 2% v/v 
whole, normal guinea pig serum. 
b)Leukocyte + Candida mixtures were exposed to the specific 
SM-1213 concentrations noted above contained in HI-WOs/ 
BA2000 tissue culture medium during the initial incubation 
time at 37°C, 5% C0 2 • 
c)Percentage viable cells was determined as in Figure 3. 
d)Initial incubation time in TC medium before the additional 
two and one-half hours of incubation on Sabouraud's dex-
trose agar at 37°C. 
e)N.D. = not done. 
f)An asterisk (*) denotes a significantly reduced percentage 
viability of C.albicans between the control and drug 
treated samples (P<O.OOl by x2 analysis). 
Theoretically, if all extracellular Candida were 
removed by the wash with medium at the 2-hour interval, 
the percentage of leukocytes containing Candida intra-
cellularly should remain constant at each sampling time 
for any given group. The percentages ranged from as low 
as 13% at 2 hours after incubation to as high as 20% 
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after 6 hours of incubation. The initial ratio of Candida 
to peritoneal cell was 1:10 to 1:5 (10-20%) in all exper-
iments. No significant differences were observed over 
time in the percentage of exudate cells containing intra-
cellular Candida. In addition, virtually all Candida 
used as an inoculum was apparently phagocytized. 
A cell-free sample of tissue culture medium was 
also inoculated with Candida. This was done to insure 
that intracellular Candida which remained in the yeast 
form (hyphal length = 0 ~) did so due to the influences 
of the peritoneal cells present (see upper half of Table 
5). At the 2-hour interval, 88% of all Candida cells 
had developed into the hyphal form; by 6 hours, 94% pro-
duced hyphae. Clearly, the majority of Candida cells, 
when not influenced by peritoneal cells, develop into 
the hyphal form in the tissue culture medium tested (HI-
W05/BA2000 with 2% whole, normal guinea pig serum). The 
longest hypha observed in this study ranged from 62 ~ at 
the 2-hour time interval to 115 ~ at the 6-hour interval. 
The longest hypha at the 4-hour interval measured 75 ~· 
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Table 5. Effect of tissue culture medium on candidal morph-
ology in the presence of seruma 
Percentage of Candida in hyphal forme 
Experiment 
numberb 
1 
2 
2 
88 
90 
Incubation time (hours) 
4 6 
92 
95 
94 
d N.D. 
a)3 ml of HI-W0 5 /BA2000 tissue culture medium containing 2% 
v/v whole, normal guinea pig serum was inoculated with 
4 X 10 5 yeast cells in the absence of leukocytes and incu-
bated at 37°C, 5% C0 2 • 
b)Experiment #1 was conducted in parallel with an experiment 
utilizing mineral oil induction and experiment #2 was con-
ducted in parallel with an experiment utilizing glycogen 
induction. 
c)50 Candida were counted from tissue culture samples at the 
intervals indicated above and examined for the formation 
of germ tubes. The number of c.albicans displaying germ 
tube formation divided by the-total number of yeast and 
hyphal forms present X 100 = % of Candida in hyphal form. 
d)N.D. = not done. 
Lastly, studies were performed in which glycogen 
induced peritoneal exudate cells were incubated with 
whole, normal guinea pig serum added to the tissue cul-
ture medium (see Figure 7). In this study, which was 
performed blind, the drug groups once again showed sig-
nificantly less germ tube elongation than the control. 
However, unlike the other experiments discussed, the 
highest drug concentration appeared to be the most effi-
cient in inhibiting intracellular Candida growth. 
All drug groups demonstrated significantly fewer 
viable Candida cells than the controls under the influ-
ence of serum (see Figure 8 and Table 6). 
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The percentage of Candida in hyphal form in samples 
containing no exudate cells was determined as in the 
previous experiment to confirm that inhibition of germ 
tube elongation was truly due to the presence of leuko-
cytes (see lower half of Table 5) . Both the glycogen 
induced and paraffin oil induced studies contained serum 
in the tissue culture medium and, in both, approximately 
90% of the Candida cells developed into the hyphal form 
by 2 hours of incubation. 
The range in hyphal length was marginally greater 
in this study than in the last when comparing lengths of 
the longest germ tube observed at a particular time 
interval. After 2 hours of incubation, the longest hypha 
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Figure 7. Effect of SM-1213 on germ tube elongation 
of phagocytized Candida albicans in glycogen induced exudate 
cells in the presence of serum. 
Procedures were identical to those described in Fig-
ure 4 except, in this case, 2% v/v whole, normal guinea pig 
serum was added to the incubation medium. Each point repre-
sents the average germ tube length (±S.E.) of 50 intracellu-
lar Candida cells at the designated time interval. (e) Con-
trol;(+) 0.1 ~g SM-1213/ml TC medium;(£) 0.01 ~g SM-1213/ml 
TC medium; (T) 0.001 ~g SM-1213/ml TC medium. 
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Figure 8. Effect of SM-1213 on the viability of 
phagocytized Candida albicans in glycogen induced exudate 
cells in the presence of serum. 
Each point represents the percentage of viable 
Candida cells in 100 leukocytes containing fungus. Percent-
age v1ability was determined as in Figure 3. (e) Control; 
(+) 0.1 ~g SM-1213/ml TC medium during initial incubation; 
(A) 0.01 ~g SM-1213/ml TC medium during initial incubation; 
(T) 0.001 ~g SM-1213/ml TC medium during initial incubation. 
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Table 6. Effect of SM-1213 concentration on the viability of 
intracellular Candida albicans in the presence or 
absence of serum 
Percentage viable Candida albicans a SM-1213 
concentration d (~g/ml)b Mineral oilc Glycogen 
No Serum e No Serum e serum serum 
0 85 79 54 52 
0.001 66*f 56* 34* 34* 
0.01 75 74 42 30* 
0.1 N.D.g 72 47 35* 
a)% Viability= #of Candida forming colonies X lOO; 
# of Candida # of Candida unable 
forming colonies + to form colonies 
a colony was designated as four adjacent C.albicans yeast 
cells formed on Sabouraud's dextrose agar-after two and 
one-half hours of incubation at 37°C. 100 leukocytes were 
counted for each percentage. 
b)Leukocyte +Candida mixtures were exposed to the specific 
SM-1213 concentrations noted above contained in HI-W0 5 / 
BA2000 tissue culture medium during the initial 6 hours 
of incubation at 37°C, 5% C0 2 • 
c)Mineral oil was injected i.p. into a guinea pig 72 hours 
prior to leukocyte harvest. 
d)Glycogen (0.1% w/v in EBSS) was injected i.p. into a 
guinea pig 24 hours prior to leukocyte harvest. 
e)Initial incubation medium contained 2% v/v whole, normal 
guinea pig serum. 
f)An asterisk (*) indicates a significant difference in per-
centage viable c.albicans between control and drug treat-
ed samples (P < 0.05 by the x2 analysis). In addition, gly-
cogen induced cells demonstrated a significantly reduced 
candidal viability relative to mineral oil induced cells 
in the presence or absence of serum (P < 0.01 by x2 anal-
ysis). 
g)N.D. =not done. 
Data was compiled from four experiments. 
observed measured 37 ~' at 4 hours 94 ~' and at 6 hours 
no reading was taken. 
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The average germ tube length in the cell-free 
sample was significantly greater than any test group 
containing peritoneal cells and is illustrated in Table 7. 
The addition of serum to the tissue culture medium 
had the effect of reducing the average germ tube length 
for every group tested which contained cells (see lower 
half of Table 3). Serum had a similar inhibitory effect 
on the average germ tube length in the paraffin oil in-
duced experiments, but only in the control group at the 
6-hour sampling time was a significant difference noted. 
Although the average germ tube length was not 
significantly affected by serum in comparable glycogen 
samples, the frequency of Candida remaining in the yeast 
form after 6 hours incubation was significantly affected 
(see Table 8). Therefore, there apparently was an effect 
mediated by the addition of serum which inhibited hyphal 
formation in glycogen induced cells (control and drug 
treated) as well as in the control paraffin oil induced 
cells. Drug treated cells from the paraffin oil induced 
studies were once again not significantly affected by the 
addition of serum. 
Average germ tube length closely correlated to the 
percent viability as determined in these studies. The 
Table 7. Effect of glycogen induced exudate cells on germ 
tube elongation of phagocytized Candida albicans 
in the presence of seruma 
Experimental 
group 
b Average germ tube length (~) 
Incubation time (hours) 
2 4 6 
59 
Leukocytes 
+ mediumc 
d . d Me lUm 
1.04 ± 0.28*e 
16.10 ± 1.55 
2.86 ± 0.89* 
34.66 ± 3.85 
6.80 ± 1.58 
N.D.f 
a)2% v/v whole, normal guinea pig serum was added to the in-
cubation medium. 
b)SO candidal cells were measured for germ tube elongation 
by the use of a micrometer in the eyepiece of a microscope 
at lOOOX at the intervals detailed above. Average germ 
tube lengths are represented plus or minus the standard 
error of the mean (±S.E.). 
c)3 ml of HI-W0 5/BA2000 tissue culture medium containing 
serum as detailed in (a) was inoculated with 4 X 10 5 yeast 
cells in the presence of 2 X 106 glycogen induced perito-
neal cells and incubated at 37°C, 5% C0 2 . 
d)3 ml of HI-W0 5 /BA2000 tissue culture medium containing 
serum as detailed in (a) was inoculated with 4 X 10 5 yeast 
cells in the absence of exudate cells and incubated at 
37°C, 5% C0 2 for the indicated time intervals. 
e)An asterisk (*) indicates a significantly reduced average 
germ tube length of Candida in samples containing exudate 
cells (P < 0. 01 by Student's t test) . 
f)N.D. = not done. 
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Table 8. Effect of SM-1213 concentration on the morphology 
of phagocytized Candida albicans in the presence 
or absence of serum 
SM-1213 
concentration 
( )lg/ml) a 
Mineral oild 
0 
0.001 
0.01 
e Glycogen 
0 
0.001 
0.01 
0.1 
Frequency of Candida albicans 
in yeast formb 
No serum 
0/50 
4/50 
1/50 
17/50 
17/50 
11/50 
Serumc 
11/50 
9/50 
5/50 
29/50* 
30/50 
39/50 
42/50 
Significance 
levelf 
P<O.OOl 
N.S. 
N.S. 
p < 0. 001 
p < 0. 01 
p < 0. 001 
p < 0. 001 
a)Leukocyte + Candida mixtures were exposed to the specific 
SM-1213 concentrations noted above contained in HI-W0 5 / 
BA2000 tissue culture medium during the initial 6 hours of 
incubation at 37°C, 5% C02 • 
b)50 C.albicans cells contained within leukocytes were exam-
ined for germ tube formation after 6 hours of incubation 
time under the conditions described in (a). 
c)Incubation medium contained 2% whole, normal guinea pig 
serum. 
d)Mineral oil was used as an inducing agent for leukocyte 
harvest; 20 ml was injected i.p. into a male, Hartley 
strain guinea pig 72 hours prior to cell harvest. 
e)Glycogen was used as an inducing agent; 20 ml of a 0.1% 
w/v solution of glycogen in EBSS was injected as in (d) 
above except 24 hours prior to cell harvest. 
f)N.S. indicates P < 0.05 by the x2 analysis. 
g)Glycogen induced leukocytes demonstrated a significantly 
greater number of Candida cells in the yeast form than the 
mineral oil induced cells in the presence of serum 
(P< 0.05 by the x2 analysis). 
correlation was strongest in the absence of serum in both 
the glycogen and paraffin oil studies (Pearson's r = 
0.99). The correlationwasmoderately strong in the par-
affin oil study with serum (r = 0.74) and strong in the 
glycogen study with serum added (r = 0.94). 
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As will be discussed later, the differences in the 
cell type which predominated in the peritoneum as a result 
of the inducing agent employed may provide an explanation 
for the differences observed between paraffin oil induced 
cells and glycogen induced cells. The predominant cell 
type produced upon 72-hour paraffin oil induction was the 
macrophage, whereas the predominant cell type upon 24-hour 
glycogen induction was the polymorphonuclear leukocyte. 
As demonstrated in Table 9, not only was the effect 
of serum on the germ tube length different upon paraffin 
oil induced cells than glycogen induced cells, but the 
overall length attained by germ tubes after 6 hours incu-
bation was significantly lower in glycogen induced cells. 
In addition, glycogen induced cells also demonstrated a 
lower percentage of hyphal forms of Candida in the pres-
ence and absence of serum than did the paraffin oil 
induced cells. These attributes may reflect the greater 
candidacidal activity of the polymorphonuclear neutrophil. 
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Table 9. Effect of serum on germ tube formation in phagocyt-
ized Candida albicans in tissue culture 
Leukocyte Average germ tube length ( ll) a Significance inducing 
c leveld agentb No serum Serum 
Mineral 52.68 ± 3.83 27.94 ± 3.69 p < 0. 001 
oil (100%)e (7 8%) 
Glycogen 9.34 ± 1. 74*£ 6.80 ± 1. 58* N.S. 
(84%)* (42%) * 
a)SO C.albicans cells contained within leukocytes were meas-
ured for germ tube length after 6 hours of incubation time 
in HI-W0 5 /BA2000 tissue culture medium at 37°C, 5% C02 • 
Germ tube lengths were measured by the use of a micrometer 
in the eyepiece of a microscope at lOOOX. 
b)20 ml of mineral oil or glycogen (0.1% w/v in EBSS) was 
injected i.p. into a male guinea pig 72 or 24 hours prior 
to leukocyte harvest respectively. 
c)Incubation medium contained 2% v/v whole, normal guinea 
pig serum. 
d) N. S. = not significant (P > 0. 05 by Student's t test) . 
e)Percentages in parentheses indicate the percentage of 50 
intracellular Candida cells which developed germ tubes 
(hyphae) after 6 hours of incubation time as described in 
(a). Although the addition of serum did not significantly 
reduce the germ tube length of Candida in the glycogen 
induced studies, the percentage of Candida in hyphal form 
was significantly reduced (P < 0. 001 by x 2 analysis) by the 
addition of serum to the culture medium. In addition, the 
presence of serum in the culture medium significantly re-
duced the percentage of hyphae formed in the mineral oil 
induced studies as well (P < 0. 001 by x2 analysis) . 
£)Glycogen induced leukocytes demonstrated a significantly 
reduced germ tube length relative to mineral oil induced 
cells in the presence or absence of serum (P < 0. 001 by 
Student's t test) as well as a significantly reduced per-
centage of Candida in hyphal form (P < 0.01 by x2 analysis) 
as indicated by asterisks above. 
B. In Vivo Studies 
1. Intravenous Inoculations 
a. Computation of the 50% Lethal Dose (LDso) of Candida 
albicans 
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The results for the determination of the 50% lethal 
dose for the strain of Candida albicans used in the fol-
lowing experiments is shown in Table 10. By day 11, an 
intravenous dose of 1 X 10 5 • 88 Candida cells, grown for 
24 hours on SDA at 37°C, will be lethal to 50% of male, 
Ha/ICR mice used experimentally. Initial intravenous 
experiments were primarily concerned with early mortality 
occurring within the first week following infection where 
high doses of Candida were used as inocula. Day 11 was 
therefore chosen for the termination of tbe LDso study. 
Subsequent experiments in which low inocula were used 
were conducted for more prolonged periods and mortality 
was observed for approximately 30 days, although no fur-
ther LD 50 studies were conducted. 
b. Effect of SM-1213 on Mortality of Mice Infected Intra-
venously with Candida albicans 
A series of studies were undertaken to determine 
the effect of SM-1213 drug administration on intravenous-
ly infected Ha/ICR mice. SM-1213 therapy for 24 hours 
only beginning either on the day of infection (day 1) or 
24, 48, or 72 hours post-infection was examined. SM-1213 
Table 10. Computa·tion of the 50% lethal dose (LD 50 )* for Candida albicans by day eleven 
post-infection. 
Accumulated values 
Candida dose Mortality Total Total Mortality injected i.v. ratio Died Survived dead survived Ratio % Dead 
1 X 10 8 8/8 8 0 19 0 19/19 100 
1.5 X 10 7 7/8 7 1 11 1 11/12 92 
1 X 10 6 4/6 4 2 4 3 4/7 57 
1 X 10 5 0/6 0 6 0 9 0/9 0 
*Calculation of the LD 50 from the above data: 
% Mortality at dilution next above 50% - 50% 
%Mortality at dilution next above 50%-% Mortality-at dilution next below 50% 
Proportionate distance between known % mortality 
and 50% mortality 
Therefore, 57% - 50% 
= 0.12 Or, the LD 50 titer= 105.88 57% - 0% 
= 
(j) 
,j:::. 
was administered in the drinking water at a dosage of 80 
~g/kg/day based on average consumption per average as-
sessed animal weight. 
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In male, Ha/ICR mice infected with 2 X 10 5 Candida 
cells intravenously and treated 48 hours later with SM-
1213 for 24 hours, a significant reduction in mortality 
was observed when compared to control mice (see Figure 9). 
In order to substantiate these results, two addi-
tional experiments were conducted under the same experi-
mental protocol as the first. Table 11 illustrates the 
cumulative mortality for all three experiments conducted 
utilizing the day 3-4 drug treatment regimen. Significant 
differences were obtained between the drug treated and 
control groups in cumulat~ve mortality from day 18 to 
day 24. Table 12 illustrates the continued significant 
differences on day 27 and day 30 in two of the three 
experiments. The third experiment was altered on day 24 
and the results beyond this day (and therefore before 
this day) could not be included in this table. Mortality 
plateaued in all test groups from day 27 until experi-
mental termination. 
In addition, alternate intervals of drug adminis-
tration were tested (see Table 13). Various intervals of 
24-hour drug treatment were tested in these experiments: 
1) drug treatment begun on the day of infection for 24 
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Figure 9. Effect of SM-1213 therapy on the cumulative 
mortality of mice infected intravenously with Candida albi-
cans. 
5Male, Ha/ICR mice were injected intravenously with 2 X 10 c.albicans cells on day 1. Drug treated mice receiv-
ed 80 ~g-SM-1213/kg/day orally in drinking water for day 3 
to day 4 only; control mice received no drug. (e) Control, 
N = 15; (+) SM-1213 treated, N = 15. 
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Table 11. Effect of SM-1213 treatment on the cumulative percentage mortality in mice 
infected intravenously with Candida albicansa 
Treatment 
group 
Control 
SM-1213c 
Day 9 
3 
3 
Cumulative % mortalityb 
Day 12 Day 15 Day 18 Day 21 
25 41 53 58 
18 28 34*d 38* 
Day 24 
64 
43* 
(Number of 
experiments) 
(3) 
N=59 
( 3) 
N=61 
a)Male, Ha/ICR mice were infected intravenously with 2 X 10s C.albicans cfu on day 1 
and observed for the occurrence of death. -
b)The cumulative percentage mortality was determined for the days indicated above by 
determining the total number of mice dead by that day divided by the total number 
of experimental animals X 100. N = the total number of mice used experimentally. 
c)Drug treated mice received 80 ~g SM-1213/kg/day orally in the drinking water for 
24 hours only from day 3 to day 4 post-infection. 
d)An asterisk (*) indicates a significant reduction in cumulative mortality in drug 
treated mice relative to control mice (P < 0.05 by x2 analysis). 
0\ 
Cf) 
Table 12. Effect of SM-1213 treatment on the thirty day cumulative mortality in mice 
infected intravenously with Candida albicansa 
Treatment Cumulative % mortalityb 
group Day 9 Day 12 Day 15 Day 18 Day 21 Day 24 
(Number of 
Day 27 Day 30 experiments) 
Control 5 38 57 62 
SM-1213c 8 21 32*d 42 
68 78 
42* 45* 
78 
50* 
78 
50* 
(2) 
N=37 
( 2) 
N=38 
a)Male, Ha/ICR mice were infected intravenously with 2 X 10 5 c.albicans cfu on day 1 
and observed for the occurrence of death for thirty days. -
b)The cumulative percentage mortality was determined as indicated in Table 11. N = 
the total number of animals used experimentally. 
c)Drug treated mice received 80 ~g SM-1213/kg/day orally in drinking water for 24 
hours only for day 3 to day 4 post-infection. 
d)An asterisk indicates P < 0.05 by the x2 analysis between control and drug treated 
group mortality. 
ffi 
~ 
Table 13. Effect of SM-1213 treatment on the cumulative mortality of mice infected intra-
venously with Candida albicans and treated with SM-1213 at various intervalsa 
Treatment 
group Day 9 
Control 4(±2)c 
**Day 1-2 7 ( ± 7) 
**Day 2-3 2 ( ±2) 
**Day 3-4 6 ( ±4) 
**Day 4-5 5(NA)e 
Average cumulative % mortalityb 
Day 12 Day 15 Day 18 Day 21 
28(±12) 43(±16) 54 (±9) 59(±9) 
22 (±9) 33(±16) 48(±18) 61 (±13) 
9(±5)*d 20(±7)* 34(±7)* 48 (±7) 
17(±4) 26 (±9) 34(±8)* 37(±6)* 
14(NA) 23(NA) 27(NA)* 27(NA)* 
Day 24 
67(±14) 
68(±11) 
61(±11) 
42(±3)* 
32(NA)* 
(Number of 
experiments) 
(3) N=59 
(2) N=46 
(2) N=44 
(3) N=61 
(1) N=22 
a)Male, Ha/ICR mice were infected intravenously with 2 X 10 5 Candida albicans cells on 
day 1 and observed for the occurrence of death. Drug treated mice received 80 ~g SM-
1213/kg/day orally in drinking water for 24 hours only for the interval designated by a 
double asterisk above (**). 
b)The cumulative mortality for each designated time interval from day 9 to day 24 was de-
termined by averaging the cumulative mortality of animals from multiple experiments. 
c)The average cumulative percentage mortality is expressed plus or minus the standard 
error of the mean (±S.E.). 
d)An asterisk (*) following the S.E. indicates a significant reduction in average cumula-
tive mortality in drug treated mice relative to control mice (P < 0.05 by x2 analysis). 
e)NA = not applicable. 
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hours only (designated as day l-2 therapy), 2) treatment 
begun on the day following infection (day 2-3), 3) treat-
ment begun 2 days following infection (day 3-4), and 4) 
treatment begun 3 days following infection (day 4-5). 
Table 13 represents the average cumulative percentage 
mortality for all three experiments. The earliest sig-
nificant difference in mortality between drug and control 
groups occurred in the day 2-3 treated group. However, 
mortality continued to rise in the day 2-3 treated mice 
and was not significant from the control group on day 
71 
21 or 24. The day 3-4 treated group showed a significant-
ly lower cumulative mortality than controls during exper-
imental continuation from day 18 to day 24. Day 4-5 data 
was included in this table even though-one experiment was 
conducted using this regimen and was not conclusive evi-
dence that a significant difference between control and 
drug groups was truly present. The day 4-5 treated group 
showed a significantly lower cumulative mortality than 
the average control from day 18 to day 24. However, this 
treatment group was not significantly different from its 
own experimental control. There was an indication that 
further experiments, which would increase experimental 
numbers, would have shown a significant difference, since 
multiplication of the data from this one experiment by 
three produces a significant difference between control 
and day 4-5 treated groups from day 20 to day 24. There 
is strong evidence to support the effectiveness of day 
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3-4 drug therapy, however, in the reduction of overall 
cumulative mortality and a suggestion that day 4-5 therapy 
may be effective as well. 
In addition, day 3-4 and day 4-5 drug therapy were 
significantly more effective in reducing cumulative mor-
tality than day 1-2 drug therapy on day 21 and 24. Day 
4-5 drug therapy was also more effective than day 2-3 
drug therapy on day 24. Such data supports the suggestion 
that specific intervals of drug therapy are important in 
the effectiveness of SM-1213 in reducing mortality. 
In order to quantitate the number of yeast cells 
in the viscera of mice inoculated with Candida albicans, 
tissue homogenate studies were conducted. Since the 
kidney is an organ of major involvement in candidal in-
fections (26,66), it was of interest to culture these 
organs from infected animals. On day 32, surviving mice 
were killed by cervical dislocation and kidneys were 
aseptically removed and homogenized. 
Significant differences were not observed between 
any of the test groups at this sacrifice time. The aver-
age number of Candida cells per two kidneys homogenized 
varied from as low as 1 X 10~ (±0.64) for the drug treated 
animals to 1.7 X 10 5 (±1.7) for the control animals. 
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2. Effect of SM-1213 on the Course of Leg Lesions in Mice 
Infected Intramuscularly with Candida albicans 
A series of experiments were conducted utilizing 
the mouse leg lesion model for experimental candidiasis. 
Animal weights, as well as abscess sizes, were monitored 
at intervals throughout infection. In addition, absces-
ses, kidneys, and/or spleens were either 1) homogenized 
in order to quantitate Candida present or 2) cultured in 
order to determine the presence of Candida within these 
tissues. 
The CBA/J strain of mouse was determined to be 
suitable for these studies, since it consistently pro-
duced measurable abscesses with the inocula used in these 
experiments. The CBA/J inbred strain of mouse provided 
a more genetically homogeneous population than did the 
randomly-bred Ha/ICR strain of mouse; this would have 
been particularly important had lymphoid cell transfer 
studies been undertaken. In addition, the temperament 
of the CBA/J mouse was more docile than that of the Ha/ICR 
mouse, which not only allowed for easier handling of the 
mice but also eliminated interference with experimental 
data due to fighting among cohabitating males as observed 
in the Ha/ICR strain. 
The inbred C3H strain proved to be less susceptible 
than the CBA/J strain to Candida lesion formation and 
7~ 
required twice the inoculum of Candida to produce an 
abscess equivalent in size to that of the CBA/J strain. 
Another inbred strain of mouse, the Balb/c strain, was 
also found to be unsuitable for leg lesion studies, since 
spontaneous amputation of the infected limbs occurred by 
day 7 in 10% of the mice inoculated. Such amputation 
was attributed to a hyperimmune response, since mice 
immunosuppressed with 300 mg of cyclophosphamide/kg four 
days prior to infection did not amputate their limbs or 
develop localized abscesses. Such a dose of cyclophospha-
mide has been shown to reduce white blood cell counts in 
mice 100-fold by day 4 (58). However, immunosuppressed 
mice subsequently died of apparent systemic infection; 
by day 12, mortality reached 78%. Therefore, the CBA/J 
strain of mouse was utilized in the following studies. 
a. Leg Lesion Study #1: Effect of SM-1213 on the Course 
of Leg Lesions in Mice Infected Intramuscularly with 
1.25 X 10 8 Candida albicans Cells 
In this study, designated as Leg Lesion Study #1, 
male CBA/J mice were infected with 1.25 X 10 8 Candida 
cells per mouse intramuscularly into the right calf. 
Leg swelling was measured on day 1, 2, 3, 6, 7, 8, 10, 
13, 15, 17, 20, 22, and 24. Drug therapy (80 ~g/kg/day) 
was administered from day 3 to 4 for one treatment group 
and day 4 to 5 for the other treatment group. As shown 
in Figure 10, there were no significant differences in 
abscess sizes between drug and control groups until day 
24. 
Animal weights, however, were significantly higher 
in drug treated animals (see Figure 11) , which suggested 
that these animals were in better overall health (57); 
SM-1213 has no caloric value due to the substitutions 
present on the monosaccharide molecule. The average 
group weight change from prior to infection to various 
intervals post-infection is shown in Figure 11. Drug 
treated mice more closely paralleled the weight gain 
pattern demonstrated by uninfected control mice than did 
the infected controls. 
When differences in animal weights were corrected 
for any contributions the abscess sizes may have added, 
the significant differences in animal weight between the 
drug treated and control mice were actually enhanced 
moderately (P<0.02 on day 8, P<O.Ol on day 15, and P 
was the same on day 22). 
In addition, when convalescing mice were analyzed 
for Candida content in spleens on day 24, it was dis-
covered that the day 4-5 drug treated groups had a sig-
nificantly lower incidence as well as number of Candida 
than controls (see Table 14). 
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Figure 10. Effect of SM-1213 on the course of leg lesions in mice infected 
intramuscularly with 1.25 X 108 Candida albicans cells. 
Candida cells were injected on day 1. Leg swelling was measured at the des-
ignated time 1ntervals with the aid of a Schnellt~ster numerical dial caliper. Drug 
treated groups received 80 ~g SM-1213/kg/day orally in drinking water either for 
day 3 to day 4 post-infection (Rxl) or for day 4 to day 5 post-infection (Rx2) . The 
original number of mice in each test group was as follows: (e) Control, N = 14; 
(•) day 3 to 4 drug treated group, N = 14; and (~) day 4 to 5 drug treated group, 
N = 14. 
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Figure 11. Effect of SM-1213 on the average group 
weight change fro~ day one in mice infected intramuscularly 
with 1.25 X 108 Candida albicans cells. 
CBA/J mice were weighed prior to infection on day 1 
and on days thereafter as indicated at right. The difference 
between the average group weight on day 1 and on subsequent 
days was plotted. The original number of test animals was 
as follows: (•) Control, N = 14; (T) day 4 to 5 drug treat-
ment group (as described in Figure 10), N = 14; (A) day 3 
to 4 drug treatment group (as described in Figure 10), 
N = 14; and uninfected control group (injected with PBS only 
in the right leg), N = 8, represented at right by a star. 
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Table 14. Effect of SM-1213 on the number of Candida albicans 
recovered from spleens of convalescing micea 
Treatment 
b Interval 
Control 
Day 4-5 
Frequency of spleens 
containing 
viable C.albicansc 
13/14 
8/14 
Frequency of spleens 
containing ~ 50 d 
viable C.albicans 
13/14 
4/14 
a)Male, CBA/J mice were injected intramuscularly in the right 
calf with 1.25 X 10 8 c.albicans cells on day 1. On day 24, 
mice were sacrificed;-spleens were excised, homogenized and 
assessed for colony forming units on SDA at 37°C. 
b)Control mice received no drug; drug treated mice received 
80 ~g SM-1213/kg/day orally in the drinking water for 24 
hours only from day 4 to day 5 post-infection. 
c)Control mice versus drug treated, P < 0.05 by x2 analysis. 
d)Control mice versus drug treated, P < 0.001 by x2 analysis. 
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These results suggest that the drug treated groups 
were better able to contain the abscess and prevent the 
systemic spread of the infection. However, no significant 
differences were obtained between drug and control mice 
in tissue homogenates of the kidneys (1.15 X 10 3 ± 0.29 
versus 2.81 X 10 3 ± 0.68) when such high levels of Candida 
were injected. An alternative suggestion would be that 
drug treated mice were better able to clear Candida from 
the spleens by day 24. 
b. Leg Lesion Studies #2 and #3: Effect of Altered 
SM-1213 Drug Regimen and Method of Drug Administration 
on Mice Infected Intramuscularly with Candida albicans 
An inoculum similar to that used in Leg Lesion 
Study #1 was used (1.2 X 10 8 Candida cells per mouse) and 
CBA/J mice were inoculated intramuscularly into the right 
leg. However, in these studies drug regimen was altered. 
Also, the method of drug administration was altered in 
one of the following two experiments. 
In addition to administering drug by drinking water 
only, the method of gavaging animals to administer drug 
was initiated. In Leg Lesion Study #2, day 4-5 drinking 
water treatment was given as in Leg Lesion Study #1 (80 
~g/kg/day); however, an additional drinking water dose 
was also given for day 7-11 (400 ~g/kg/day). In Leg 
Lesion Study #3, gavage doses were given for day 1-4 (400 
~g/kg/day) , followed by drinking water administration 
of drug for day 7-11 (400 ~g/kg/day) and day 17-18 (80 
~g/kg/day). See Figures 12 and 13. 
Using these drug regimens, significant differ-
ences occurred between abscess sizes of drug treated 
and control groups. Drinking water therapy showed the 
most significant differences early in the infection, 
while gavage therapy demonstrated greatest significance 
later in infection. 
Tissue homogenization of kidneys and spleens was 
carried out on day 46 post-infection. No significant 
differences were found in the spleens as in Leg Lesion 
Study #1, where mice were sacrificed on day 24. How-
ever, almost twice the number of Candida was found in 
control kidneys as compared to mice treated with drug 
by gavage. 
c. Sustained Effect of SM-1213 Treatment on Mice from 
Leg Lesion Study #2 Reinoculated Intramuscularly 
with Candida albicans 
The recovered mice from Leg Lesion Study #2 were 
reinfected on day 57 in the uninfected leg with 1 X 10 5 
Candida cells per mouse intramuscularly (i.e. left leg 
was injected) . Significant differences were detected 
between control and previously drug treated groups on 
day 4 and 5 following reinoculation (see Figure 14). 
The significant differences observed in the reinfected 
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Figure 12. Effgct of altered SM-1213 drug regimen on mice infected intramus-
cularly with 1.2 X 10 Candida albicans cells. 
ro 
w 
Leg swelling was measured at the days indicated above with the aid of a 
Schnellt~ster numerical dial caliper. Drug treated groups received 80 ~g SM-1213/kg/ 
day for day 4 to day 5 post~infection as in the initial leg lesion study as well as 
an additional 400 ~g SM-1213/kg/day drug treatment for day 7 to day 11. All drug was 
administered in the drinking water. (e) Control, N = 12; (0) SM-1213 treated, N = 12. 
Points of significant differences in leg swelling between control and drug treated 
groups is indicated below by a star. 
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Figure 13. Effect of altered method of SM-1213 administration on mice infect-
ed intramuscularly with 1.2 X 10 8 Candida albicans cells. 
Leg swelling was measured at the days indicated above with the aid of a 
Schnellt~ster numerical dial caliper. Drug treated groups received 400 ~g SM-1213/kg/ 
day by gavage for day 1 to day 4, 400 ~g SM-1213/kg/day in drinking water for day 7 
to day 11, and 80 ~g SM-1213/kg/day in drinking water for day 17 to day 18. (e) Con-
trol, N = 12; (0) SM-1213 treated, N = 14. Points of significant differences in leg 
swelling between control and drug treated groups is indicated below by a star. 
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Figure 14. Sustained effect of SM-1213 treatment on 
mice reinoculated intramuscularly with Candida albicans. 
CBA/J mice, originally infected l.m. Wlth 1.2 X 108 
Candida albicans cells were reinoculated in the contralater-
al leg Wlth 1 X 105 Candida cells on day 57 post-initial in-
fection. No additional drug therapy was given. (e) Control, 
N = 11; (•) SM-1213 treated, N = 10. 
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mice occurred without additional drug administration. 
Thus, SM-1213 therapy exerted an effect long after the 
initial infection had been resolved. 
d. Leg Lesion Study #4: Effect of SM-1213 on the Course 
of Leg Lesions in Mice Infected Intramuscularly with 
7 X 10 6 Candida albicans Cells 
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In an attempt to reduce systemic infection and to 
produce a localized, limited lesion, the dosage of Candida 
injected intramuscularly was reduced in the following two 
experiments. Male, CBA/J mice inoculated with 7 X 10 6 
Candida cells per mouse were monitored regularly for leg 
swelling, as shown in Figure 15. Drug was administered 
in the drinking water for day 4 to 5 (80 ~g/kg/day) and 
day 7 to ll (400 ~g/kg/day). Significant differences 
between control and drug treated abscess sizes were ob-
tained with this Candida dosage and drug regimen. 
Tissue homogenates of spleens and kidneys of both 
control and drug treated mice were negative for any can-
didal colony forming units on day ll. Before drug therapy, 
the abscess sizes of the SM-1213 treated test group were 
not significantly different from the controls; however, 
by day 7 the abscesses from the drug treated animals were 
significantly smaller than those of the controls. 
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Figure 15. Effect of SM-1213 on the course of leg le-
sions in mice infected intramuscularly with 7 X 106 Candida 
albicans cells. 
Leg swelling was measured as in Figure 10. Drug 
treated groups received 80 ~g SM-1213/kg/day orally in the 
drinking water from day 4 to 5 and 400 ~g SM-1213/kg/day for 
day 7 to 11. (e) Control, N = 30; (~) SM-1213 treated, 
N = 30. 
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e. Leg Lesion Study #5: Effect of SM-1213 on the Course 
of Leg Lesions and Metastasized Fungus in Mice In-
fected Intramuscularly with 7 X 10 6 Candida albicans 
Cells 
This study repeated the experimental procedure of 
the last study (Leg Lesion Study #4); however, instead of 
homogenizing tissues, kidneys, spleens, or abscesses were 
cultured. This method was adopted in order to determine 
any presence of Candida in these tissues which may not 
have been detected by ordinary homogenization techniques. 
Culturing techniques allowed for the determination of 
candidal incidence or frequency in these tissues even 
when present in small numbers. Male, CBA/J mice were 
infected with 7 X 10 6 Candida cells per mouse intramus-
cularly; drug therapy was as in Leg Lesion Study #4. 
Two sets of animals were sacrificed. The first 
set consisted of ten animals each from the control and 
drug groups which had the largest abscesses on day 8. 
The spleens, kidneys, and abscesses were removed and 
cultured. No Candida was found in the spleen, while 2 
out of 10 control animals and 3 out of 10 drug treated 
mice demonstrated Candida present in kidney cultures. 
All mice in both test groups contained Candida within 
cultured abscesses. 
The second set of animals which were sacrificed 
consisted of the next ten largest abscesses in each 
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experimental group as determined on day 11. Spleens and 
kidneys were not cultured from these animals, but abscesses 
were cultured. As above, all test animals demonstrated 
Candida present in abscess cultures (10 out of 10 each 
for control and drug treated groups). 
Highly significant differences in abscess sizes 
were obtained between control and drug treated groups 
utilizing this drug regimen, similar to those obtained 
in the last leg inoculation study (see Figure 15) . 
Uninfected control mice (injected with PBS) had 
an average "abscess" size of 0.0 ± 0.01 over the entire 
experimental time period (N = 9). 
Total numbers of mice used in this study to deter-
mine average abscess sizes were: Control, N = 30; drug 
treated, N = 30. 
f. Leg Lesion Study #6: Effect of SM-1213 on the Course 
of Leg Lesions and Metastasized Fungus in Mice In-
fected Intramuscularly with 1.25 X 10 7 Candida albicans 
Cells 
A log less Candida than was utilized in Leg Lesion 
Study #1 was inoculated into CBA/J mice intramuscularly 
(1.25 X 10 7 cfu). Mice were treated from day 4 to 5 with 
80 ~g/kg/day and from day 7 to 11 with 400 ~g/kg/day in 
drinking water. 
Significant differences were observed on day 5, 
6, and 8 in average abscess sizes between control and 
drug treated mice (see Figure 16) . The overall average 
"abscess" size in uninfected control mice was -0.02 ± 
0. 02 (N = 8) . 
No differences in frequency of Candida occurrence 
in cultured abscesses from control and drug groups were 
noted on days of sacrifice (day 11 and 18). On day 11, 
8 out of 8 control and 8 out of 8 drug treated mice had 
Candida present within leg abscesses. On day 18, 9 out 
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of 9 control and 8 out of 8 drug treated mice had Candida 
present in leg lesions. No significant difference was 
observed between control and drug group kidneys cultured 
on day 11; however, the difference in frequency of Candida 
occurrence in the kidneys by day 18 was significant (see 
Table 15) . It was proposed that drug treatment might 
allow for a more rapid clearance of Candida from the 
kidney late in infection upon the appearance of specific 
or opsonic antibody. 
The next experiment to be discussed examines the 
long-term evolution of candidal infection in the kidney. 
g. Leg Lesion Study #7: Effect of SM-1213 on the Quan-
tity of Fungus in Leg Lesions and Kidneys of Mice 
Infected Intramuscularly with 1.25 X 10 7 Candida 
albicans Cells 
The procedure of the last experiment discussed 
was repeated in this experiment with the exception of 
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Figure 16. Effect of SM-1213 on the course of leg le-
sions in mice infected intramuscularly with 1.25 X 107 
Candida albicans cells. 
Leg swelling was measured as in Figure 10. Drug 
treated groups received 80 ~g SM-1213/kg/day orally in the 
drinking water from day 4 to 5 and 400 ~g SM-1213/kg/day 
for day 7 to 11. (e) Control, N = 20; (•) SM-1213 treated, 
N = 20. 
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Table 15. Leg lesion study #6: Effect of SM-1213 on the fre-
quency of Candida albicans present in kidneys of 
intramuscularly infected micea 
Treatment 
groupb 
Control 
SM-1213 
Significance 
levelc 
Frequency of kidneys 
containing viable 
C.albicans on day 11 
3/8 
5/8 
N.S. 
Frequency of kidneys 
containing viable 
C.albicans on day 18 
4/9 
0/8 
p < 0. 05 
a)Male, CBA/J mice were injected intramuscularly in the 
calf with 1.25 X 10 7 C.albicans cells on day 1. On day 11, 
and day 18 post-infection, mice were sacrificed; kidneys 
were excised, cultured, and assessed for the presence of 
colony forming units on SDA at 37°C. 
b)Control mice received no drug; SM-1213 treated mice re-
ceived 80 ~g SM-1213/kg/day for day 4 to day 5 post-infec-
tion and 400 ~g SM-1213/kg/day for day 7 to day 11 orally 
in drinking water. 
c) N. S. = not significant (P > 0. 05 by x 2 analysis) • 
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tissue homogenizations supplementing culturing techniques. 
A truly quantitative analysis could then be performed in 
addition to a qualitative analysis. Tissue homogeniza-
tions were performed on the kidneys at day 4, 11, and 18. 
In order to insure that the absence of Candida from the 
kidneys of drug treated mice on day 18 was not an arti-
fact of homogenization, the kidneys of mice sacrificed 
on day 27 were cultured. 
Kidney homogenates of control and drug treated 
mice showed no significant difference in Candida occur-
rence at day 4 (prior to treatment) or at day 11 sacri-
fices. By day 18, however, significant differences were 
observed (see Table 16). By day 27, culturing techniques 
showed that Candida had been cleared from the drug treated 
kidneys but not from the control kidneys (see Table 16 
and Figure 17). Frequency of Candida occurrence is shown 
in parentheses in Figure 17 and 18. 
The course of leg lesion development was much like 
that observed for the last experiment; however, abscess 
sizes were significantly different between control and 
drug treated groups on day 8 and 12 (see Figure 16). 
Abscess sizes were not significantly different on days 
of sacrifice and the total number of Candida present in 
abscesses and the frequency of candidal occurrence were 
not significantly different (see Figure 18). By day 27, 
Table 16. Leg lesion study #7: Effect of SM-1213 on the frequency of Candida albicans 
present in kidneys of intramuscularly infected micea 
Control 
SM-1213c 
Significance 
leveld 
Frequency of kidneys containing viable C.albicans 
Day 4b 
3/4 
4/4 
N.S. 
Day 11 
3/10 
2/10 
N.S. 
Day 18 
7/10 
0/10 
p < 0. 01 
Day 27 
3/11 
0/10 
N.S. 
a)Male, CBA/J mice were injected intramuscularly in the right calf with 1.25 X 10 7 
C.albicans cells on day 1. On day 4, 11, 18, and 27 mice were sacrificed; kidneys 
were exc1sed and homogenized on day 4, 11, and 18 and assessed for cfu on SDA at 
37°C. On day 27, kidneys were excised, minced aseptically, and incubated in SDB for 
24 hours at 37°C; cultures were then assessed for the presence or absence of cfu. 
b)Day post-infection when 'mice were sacrificed. 
c)Control mice received no drug; SM-1213 treated mice received oral drug therapy as 
described in Table 15. 
d)N.S. = not significant (P > 0.05 by x2 analysis). 
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Figure 17. Effect of SM-1213 on the clearance of Candida albicans from the 
kidneys of mice injected intramuscularly with 1.25 X 107 colony forming units. 
,....... 
0 
0 
Mice were sacrificed at day 4, 11, and 18; kidneys were excised, homogenized, 
and assessed for cfu by plating serial dilutions of the homogenate on SDA. The ratio 
of the number of mice found to have Candida present in the kidneys to the total num-
ber of mice sacrificed is represented in parentheses. Control mice received no drug; 
drug treated mice received 80 ~g SM-1213/kg/day for day 4 to 5 post-infection and 
400 ~g SM-1213/kg/day for day 7 to 11 post-infection orally in drinking water. The 
original number of mice in each test group was as follows: (e) Control, N = 40; 
(+) SM-1213 treated group, N = 40. 
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Figure 18. Effect of SM-1213 on the clearance of Candida albicans from the 
abscesses of CBA/J mice infected intramuscularly with 1.25 X 107 colony forming 
units. 
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Mice were sacrificed at day 4, 11, 18, and 27; abscesses were excised, homo-
genized, and assessed for cfu by plating serial dilutions of the homogenate on SDA. 
The ratio of the number of mice found to have Candida present in leg lesions to the 
total number of mice sacrificed is represented in parentheses. Control mice received 
no drug;drug treated mice received therapy as in Figure 17. The original number of 
mice in each test group was as follows: (e) Control, N = 40; C+) SM-1213 treated, 
N = 40. 
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candida had been cleared from the abscesses. Abscesses 
were homogenized at each sacrifice interval. 
The overall average "abscess" size for uninfected 
control mice was -0.01 ± 0.02 from day 4 to day 27 (N = 
10) . 
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Days of sacrifice were pre-determined before the 
beginning of this experiment based on the previous study. 
In order to further examine the kidney involvement which 
occurred in Leg Lesion Study #6, day 11 and day 18 were 
once again chosen as days of sacrifice. Day 4 (prior to 
drug treatment) and day 27 were chosen as additional days 
of sacrifice. One difficulty which arose from such pre-
determination was that sacrifices in this experiment 
happened to occur on days which did not show significant 
differences in abscess sizes between control and drug 
treated groups. For the analysis of kidney involvement, 
such sacrifice days were ideal. However, this interfered 
with an attempt to examine the relationship between the 
number of Candida within abscesses and abscess size. 
It would be of value to determine whether differences in 
the number of Candida present within abscesses occurred 
on days of significant abscess size differences between 
control and drug treated groups. No significant differ-
ences in Candida number occurred within abscesses which 
were not significantly different in size (see Figure 18). 
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Since sacrifice days did not include such days of 
significance, control and drug treated group abscess sizes 
were combined,as were the total average colony forming 
units per abscess, to determine the correlation of abscess 
size to number of Candida present within abscesses at the 
various days of sacrifice; the correlation is strong 
(Pearson's r = 0.81) for those animals sacrificed. The 
correlation between abscess size and total average colony 
forming units per abscess is also strong for the entire 
population of mice (including those not sacrificed) sug-
gesting that, on the days of sacrifice, the animals sac-
rificed were representative of the entire study (Pearson's 
r = 0.87). 
h. Leg Lesion Studies #6 and #7: Combined Data from Leg 
Lesion Studies of Mice Infected Intramuscularly with 
1.25 X 10 7 Candida albicans Cells 
The combined abscess data from Leg Lesion Studies 
#6 and #7 are shown in Figure 19. Significant differences 
in abscess sizes are demonstrated early in infection. 
Measurements of uninfected control mice are also shown 
at the bottom of the graph. 
Table 17 delineates the highly significant combined 
data obtained on day 18 for the frequency of Candida 
present in the kidneys of mice in Study #6 and #7. No 
Candida was detected in uninfected control mice kidneys. 
Figure 19. Effect of SM-1213 on the course of leg lesions in CBA/J mice in-
fected intramuscularly with 1.25 X 107 Candida albicans cells. 
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Leg swelling was measured as in Figure 10. Control mice received no drug; drug 
treated mice received 80 ~g SM-1213/kg/day for day 4 to 5 post-infection and 400 ~g 
SM-1213/kg/day for day 7 to 11 post-infection orally in drinking water. The original 
number of mice in each test group was as follows: (e) Control, N = 60; (+) SM-1213 
treated, N = 60; and (A) uninfected control (injected with PBS only in the right 
leg), N = 18. Data shown is compiled from two experiments. 
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Table 17. Leg lesion studies #6 and #7: Effect of SM-1213 
on the frequency of Candida albicans present in 
kidneys of intramuscularly infected micea 
Treatment 
b group 
Control 
SM-1213 
Uninfected 
controle 
Frequency of kidneys 
containing viable 
C.albicans on day llc 
6/18 
7/18 
0/2 
Frequency of kidneys 
containing viable d 
c.albicans on day 18 
11/19 
0/18 
0/2 
a)Male, CBA/J mice were injected intramuscularly in the calf 
with 1.25 X 10 7 C.albicans cells on day 1. On day 11 and 
day 18 post-infection, mice were sacrificed; kidneys were 
excised, homogenized, and assessed for cfu on SDA at 37°C. 
b)Control mice received no drug; SM-1213 treated mice re-
ceived therapy as described in Table 15. 
c)Control mice versus drug treated mice, P > 0.05 by x2 anal-
ysis on day 11. 
d)Control mice versus drug treated mice, P < 0.001 by x2 an-
alysis on day 18. 
e)Uninfected control mice were injected in the calf with PBS 
only on day 1. 
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Combined data for the frequency of Candida occur-
rence in abscesses revealed no significant differences 
between control and drug treated groups. On day 11, in 
both control and drug groups, 18 of 18 abscesses contained 
Candidai on day 18, in the control group 19 of 19 mice had 
recoverable Candida, while in the drug group 16 of 18 
abscesses contained Candida. Uninfected control mice had 
no recoverable Candida in the kidneys or legs. 
The following observations have also been made: 
1) Preliminary histological studies conducted on 
day 11 post-infection in this laboratory indicated that 
the central area of the leg lesion contained predominantly 
polymorphonuclear cell types, while the periphery of the 
abscess consisted primarily of mononuclear cell types. 
Histological sections were stained with hematoxylin-eosin 
(H&E) for cell differentiation analysis. 
2) Wright-Giemsa stained smears of abscess fluid 
showed the presence of predominantly polymorphonuclear 
cells and cell debris. In addition, periodic acid-Schiff-
hematoxylin (PASH) stained smears of abscess fluid on day 
4 and day 8 of infection showed numerous PAS positive 
yeast and pseudohyphal forms of Candida present. By day 
15, the number of Candida present in the fluid was reduced 
as compared to day 4 and day 8. 
3) Histological sections of the kidneys on day 11 
post-infection from mice infected in the leg muscle with 
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1.25 X 10 7 Candida cells showed the presence of polymorpho-
nuclear cells dispersed within the kidneys and both yeast 
and pseudohyphal forms of Candida were evident in the 
kidney pelvis as detected by PASH staining. Such a dis-
tribution of Candida is similar to that characterized by 
~vinbald in the chronic type of renal candidiasis (66); 
that is, similar to mice surviving intravenous infection 
for over ten days. 
CHAPTER IV 
DISCUSSION 
In Vitro Studies 
No direct candidacidal or growth inhibitory effect 
due to the presence of SM-1213 in the incubation medium 
was demonstrated against the yeast or hyphal form of 
Candida albicans (Table 1 and 2). However, SM-1213 was 
found to be effective in inhibiting intracellular germ 
tube elongation of Candida (Table 3) , as well as in re-
ducing the percentage of viable cells remaining after 
phagocytosis (Table 6). This data suggests that an in-
direct candidacidal effect was exerted by SM-1213 mediated 
by the modulation of phagocyte cell processes. 
It has been shown that guinea pig peritoneal exudate 
cells can suppress the growth of Candida albicans signifi-
cantly when compared to the unimpeded growth of this 
organism in cell-free, tissue culture medium (Table 7). 
The ability of these cells to inhibit candidal germ tube 
elongation and to kill phagocytized Candida varies, de-
pending upon the type of inducing agent used. Peritoneal 
exudate cells induced by mineral oil were less efficient 
than those elicited by glycogen in inhibiting germ tube 
elongation (Table 9), as well as in reducing the percentage 
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of viable Candida remaining after phagocytosis (Table 6). 
If these highly significant differences are due to the 
cell type produced, this would indicate that the poly-
morphonuclear cell, which predominates with glycogen in-
duction, is better able to inhibit germ tube elongation 
and to reduce the viability of intracellular Candida than 
is the oil induced macrophage. A prediction such as this 
must be weighed, however, by the fact that the inducing 
agent itself may interfere with the fungicidal abilities 
of these cells. This may be particularly true in the 
case of paraffin oil-sated macrophages. However, other 
researchers (2,36,60) have also suggested that the PMN 
provides a better defense against candidal invasion than 
the macrophage. 
In addition, the number of Candida which failed 
to produce hyphae intracellularly is significantly greater 
in the glycogen induced cells (Table 8). Apparently there 
is a mechanism whereby hyphal formation is inhibited 
within responding leukocytes. 
The addition of serum to the test medium caused an 
inhibition in the average intracellular germ tube length 
regardless of the inducing agent used (Table 3). However, 
in the oil induced control group, the germ tube length 
was significantly decreased upon the addition of serum. 
Oil induced drug treated groups were not significantly 
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reduced upon the addition of serum. Since this phenomenon 
is pronounced in the oil induced studies, it is speculated 
that SM-1213 treatment may replace an unknown serum factor 
important to the macrophage in its ability to inhibit 
intracellular germ tube elongation. Hadden et al (20) , 
working with paraffin oil induced guinea pig macrophages, 
determined that SM-1213 was capable of activating macro-
phages and increasing their phagocytosis of Listeria 
monocytogenes in relation to control samples. In addition, 
SM-1213 at a concentration of 0.12 ~g/ml significantly 
increased intracellular killing of bacteria without 
affecting the viability of the macrophage monolayer. 
In the glycogen induced studies, the differences 
in average germ tube length upon the addition of serum 
were not significantly different in parallel control or 
drug treated samples (Table 3). However, serum did produce 
a significant reduction in the number of Candida present 
which were able to transform into hyphae (Table B). In 
other words, a significantly greater number of Candida 
remained in the yeast form when serum was added. Thus, 
the presence of serum in the incubation medium has been 
demonstrated to affect the morphology of the intracellular 
Candida. The retention of Candida in the yeast form may 
play an important role in reducing candidal pathogenicity 
(37,66). 
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The transformation of Candida from the yeast to the 
hyphal form has been suggested to be important in the 
spread of infection, particularly in the kidney (66). 
Winbald (66) observed that yeast cells evaded the immune 
system by invading intraluminally into the kidney tubuli 
in hyphal form. The fungi were protected in this environ-
ment and rapidly formed mycelial masses. Leukocyte 
actions which oppose the conversion of Candida from the 
yeast to the hyphal form contribute thereby to the preven-
tion of the spread of infection. 
Although the fungal hyphae appeared to penetrate 
the cell membrane of the peritoneal cells, it is possible 
that a thin cell membrane, invisible by standard micro-
scopy, still surrounded the hyphal germ tubes. This may 
account for the appearance of a low viability while germ 
tube lengths were relatively long. 
SM-1213 significantly enhanced the ability of both 
macrophages and neutrophils to inhibit intracellular 
growth of Candida (Figure 2, 4, 7). In addition, the 
percentage of viable Candida cells was reduced in those 
samples treated with the 0.001 ~g/ml dose (Table 6). An 
explanation for the candidacidal effect of SM-1213 treated 
phagocytes may lie in the activation of such cells by the 
drug. 
Normal phagocytic activity is accompanies by ac-
tivation of oxidative metabolism in phagocytic cells. A 
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result of this activation is the generation of oxidative 
intermediates such as superoxides, hydrogen peroxide, and 
hydroxyl free radicals (23). The production of such 
"active oxygens" contributes to the destruction of in-
gested bacteria, but also results in the escape of cyto-
toxic agents into the surrounding environment. This can 
produce a detrimental effect on surrounding healthy tissue 
or on the phagocyte itself. The result is an increase in 
inflammation. It has been shown that the anti-inflarnrna-
tory effect of superoxide dismutase may be due to the 
protection of nearby tissues from damage by the superoxide 
radical itself or from its reaction with hydrogen peroxide 
and the production of secondary radicals (55). 
Upon phagocytosis of particles, normal polymorpho-
nuclear leukocytes generate chemiluminescence (light 
emission) which accompanies the activation of increased 
oxidative metabolism (23). Such chemiluminescence can be 
quantitated in a liquid scintillation spectrometer (65). 
Studies were conducted by colleagues in this labor-
atory on glycogen induced guinea pig neutrophils. Through 
the use of chemiluminescence techniques, a more prolonged 
generation of microbicidal active oxygens was detected in 
0.001 flg Sl\1-1213/ml treated samples than in controls 
following phagocytosis of Candida. 
However, the activity of Sl\1-1213 appears, in work 
being conducted at this time, to be biphasic in its effects 
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depending upon the level of drug administered (personal 
communication, P. Gordon). Glycogen elicited peritoneal 
neutrophils were examined by scintillation techniques for 
chemiluminescent activity representative of superoxide 
production upon the addition of 5 X 10 7 heat-killed 
Candida cells. Cells obtained from mice which had been 
treated with 16 mg SM-1213/kg in drinking water showed no 
increase in extracellular chemiluminescence, while con-
trols increased by 12-fold in the presence of luminal 
amplifier. No differences were detected in intracellular 
chemiluminescence between control and drug treated animal 
cells. Thus, it is suggested that the decreased produc-
tion of harmful extracellular oxidative components 
associated with decreased extracellular chemiluminescence 
produces an anti-inflammatory effect akin to that observed 
for superoxide dismutase (25). At the same time, the 
continued intracellular production of active oxygens 
allows for the destruction of micro-organisms. Thus, 
high doses (16 mg/kg) of SM-1213 treatment in vivo appear 
to be anti-inflammatory, while low doses in vitro (0.001 
~g/ml) prolong chemiluminescence. 
Also, Gordon et al (19) found that, in guinea pig 
macrophages elicited with paraffin oil and cultured at 
37°C, 5% C0 2 for 24 hours in HI-W0 5 /BA2ooo medium, 0.001 
~g SM-1213/ml caused enhanced protein secretion (150%) , 
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increased peroxidase excretion relative to controls, and 
increased acid phosphatase activity in macrophage phage-
somes. Colleagues have proposed that SM-1213 may enhance 
the microbicidal activity of the myelo-peroxidase or 
related microbicidal systems dependent upon superoxide in 
these cell types at low levels of drug. 
Studies conducted elsewhere have demonstrated the 
myelo-peroxidase system to be effectively candidacidal 
(32,35). In addition, in those patients whose immune 
systems have an impaired peroxidase system such as those 
receiving chemotherapy for metastatic cancer or those 
with advanced Hodgkin's disease or acute leukemia (36), as 
well as those with chronic granulomatous disease (3,33,34), 
while phagocytosis of Candida appeared to be normal, 
candidacidal capabilities were significantly reduced. 
Although the polymorphonuclear cell has been the primary 
focus of these studies, the mouse peritoneal macrophage 
has been demonstrated to display a similar anti-microbi-
cidal potential (42). 
Thus, while no direct fungicidal or fungistatic 
effects were observed against the yeast or hyphal form of 
~- albicans, the effects of SM-1213 in vitro can be ex-
plained as an action upon the phagocytic cells present 
and, as indicated above, are probably mediated through 
the modulation of intracellular enzymes and their secre-
tion or through other activation products. 
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In Vivo Studies 
In studies concerning mice injected intravenously 
with Candida, it was determined that the interval of drug 
administration is highly important to therapeutic effects 
(Table 13). Over a period of 24 days, cumulative mortality 
was significantly reduced in mice treated with SM-1213 for 
day 3 to day 4 post-infection. Earlier drug administration 
was less effective as the experiments progressed. It will 
be of importance, therefore, to examine the immune mechan-
isms which are involved at such time intervals, in that 
specific enhancement of fungicidal capabilities of SM-1213 
may be dependent upon the activation of a particular 
population of cell types present after the initiation of 
infection. 
A suitable model for studying experimentally in-
duced candidiasis was determined to be the mouse leg 
lesion model. A consistent, self-limiting lesion, which 
could be easily measured using a Schnelltaster caliper, 
was produced by injection of an appropriate inoculum into 
the mouse calf muscle. The enlargement of the abscess 
produced served as an indicator of the pathogenesis of the 
infection. Unlike intravenously infected mice which fre-
quently succumb to infection within two weeks, mice survive 
intramuscular infection and recover in three to four weeks 
allowing for the study of immune responses. 
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Histopathological studies conducted elsewhere (44) 
have indicated that such leg lesions are composed of a 
large number of yeasts early in infection with a modest 
cellular infiltrate during lesion development. As the 
lesion regresses, the number of fungal cells is reduced 
and the amount of host cellular infiltrate is increased. 
Histologically, the lesions have the characteristics of 
an abscess (44). 
The mechanisms of protection from candidiasis have 
been investigated by Pearsall et al (43), who suggested 
that neutrophils, along with a contribution from humoral 
immune forces, may be sufficient to limit the infection 
in mouse leg lesions. In vitro studies reported in this 
thesis (Table 9) have suggested that, indeed, neutrophils 
may be of primary importance. In addition, the presence 
of normal guinea pig serum enhanced inhibition of candidal 
germ tube formation (Table 8) , suggesting an influence of 
humoral factors [i.e. Candida albicans is so ubiquitous 
that even "normal" serum may contain antibodies to this 
organism (28) ]. 
Pearsall et al (43) also demonstrated that passive 
transfer of immune serum gave a significant degree of 
protection against lesion development in murine candi-
diasis. The transfer of resistance by sensitized lymphoid 
cells gave negative results, although cutaneous delayed 
hypersensitivity was transferred by these cells. 
There is continued controversy over the role of 
humoral and cellular immunity in candidal infections. 
In studies of experimental systemic candidiasis 
in mice intravenously injected with Candida albicans, 
complement intact mice survived significantly longer 
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than complement deficient mice. It was speculated that 
longer survival was due to the earlier and greater mobil-
ization of phagocytic cells {41). Ray {46) found the 
formation of neutrophilic microabscesses in CS-intact 
mice infected intraepidermally with Candida. C5-deficient 
mice, however, developed no inflammatory response and 
allowed the proliferation and cutaneous invasion of 
Candida. In addition, in vitro studies showed Candida-
induced neutrophil chemotaxis and complement activation. 
Giger et al {14) suggested that the acute in-
flammatory response due to cutaneous infection of mice 
with Candida albicans stimulated the production of pre-
cipitating antibody and conferred protection against 
subsequent intravenous challenge due to predominantly 
humoral response. In addition, Rogers and Balish (51) 
demonstrated that, in disseminated candidiasis, renal 
histopathology revealed a prominent role for the poly-
morphonuclear leukocyte, but not for mononuclear cells 
in the defense against systemic infection. 
The polymorphonuclear cell was also important in 
patients with chronic granulomatous disease, where 
susceptibility to candidal infection resulted from an 
abnormal function in neutrophils (33). 
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However, the cellular immune response cannot be 
overlooked as an important element in the resistance to 
candidal infection. This was especially evident in those 
individuals with chronic mucocutaneous candidiasis who 
were able to produce antibody (34) but displayed ab-
normalities in the cellular immune system (28,31). 
Successful treatment of such patients with injections of 
transfer factor or transfusions of immunocompetent lympho-
cytes support a role for thymus-dependent cellular 
immunity in protection against candidiasis (28,29). 
Controversy has arisen, however, due to evidence 
that congenitally athymic mice with deficient thymus-
dependent cell mediated immunity may actually have a 
greater capacity than normal littermates to prevent the 
growth of Candida in the kidneys and to clear Candida 
from the liver (52) . 
Reconciliation between the humoral and cellular 
defense theories has been suggested in both cutaneous 
and disseminated candidiasis. Sohnle et al (59) compared 
the pathology in chronic and acute candidal lesions in 
guinea pigs infected cutaneously with Candida. Acute 
lesions (produced by placing occlusive dressings over 
injection sites) were characterized by intense poly-
morphonuclear infiltration. In contrast, chronic lesions 
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(produced without occlusive dressings) generally presented 
an intense dermal infiltrate of mononuclear cells. How-
ever, such mononuclear infiltration was demonstrated in 
previously immunized guinea pigs, while the acute PMN 
infiltrate occurred with or without previous exposure to 
Candida. In addition, a mononuclear response could be 
acquired by those animals receiving transferred lymphoid 
cells and clearance of Candida was postulated to be asso-
ciated with lymphokine release. It would be speculated 
that, if normal and nude littermates had been previously 
exposed to Candida (immunized) , the accompanying cellular 
immune protection afforded to the kidney upon antigen 
challenge would likely be greater in normal than in nude 
littermates. 
In systemic candidiasis, Miyake et al (40), in 
experiments with intravenously infected normal, nude 
(athymic), lethally irradiated, or immunized mice, sug-
gested that non-immune phagocytosis was required early 
in infection, while T-cell mediated immunity was required 
at late stages in infection in resistance to candidiasis. 
In this case, Candida was shown to decline in the liver 
of both nude and normal littermates, but increased in 
the kidneys of nude mice. It was suggested that, since 
there are fewer fixed macrophages in the kidney than the 
liver, an accumulation of macrophages in the kidney 
123 
induced by T-lymphocyte dependent cellular immunity may be 
necessary for an effective defense against Candida in this 
organ. 
In addition, in lethally irradiated normal or nude 
AKR mice, in which phagocytic functions were decreased, 
increases in cfu were detected in both the liver and the 
kidneys from initiation of infection. Macrophages from 
irradiated mice could not as effectively inhibit the 
growth of intracellular Candida as could normal macro-
phages, as demonstrated by the more frequent formation of 
mycelia. 
Lymphoid cell transfer from AKR mice immunized 
intramuscularly with Candida demonstrated a 20% survival 
upon intravenous challenge, while few mice receiving non-
immune lymphocytes survived by day 20 (40). Prior to 
day 7, the number of cfu in the kidneys of both groups 
of mice were similar. By day 7, however, mice receiving 
immune cells showed a reduction in cfu in the kidney, 
although both groups demonstrated similar cfu in the 
liver. Normal or hyperimrnune serum was ineffective in 
reducing mortality or liver or kidney involvement. 
It appears, therefore, that, while Pearsall (43) 
found no lymphoid protection from abscess formation, 
cellular immune elements as well as phagocytic elements 
are involved in the protection of the kidney. In 
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addition, serum transfer does not afford protection in the 
kidney, while transfer of lymphoid cells does (40). 
Thus, both the Pl-1N and the macrophage, as well as 
other humoral and cellular factors, play important roles 
in resistance to candida! infection. It would be of 
interest to examine the effects of immune serum on the 
in vitro macrophage culture system in place of normal, 
whole serum previously utilized. Certainly both humoral 
and cellular elements are important in the defense against 
candidiasis and warrant further investigation. 
Mice injected intramuscularly with C. albicans and 
subsequently treated with SM-1213 showed a significantly 
higher weight gain than controls and a weight gain pattern 
more closely resembling uninfected controls (Figure 11) . 
This data, along with the lower incidence of Candida 
within the spleens of drug treated mice (Table 14), 
suggests that SM-1213 treated animals were better able 
to clear Candida which had spread systemically. Perhaps 
similar immune mechanisms are involved in the clearance 
of Candida from visceral organs in intravenous studies, 
since mice receiving a similar drug regimen and dose of 
drug as in the original leg lesion study demonstrated the 
lowest cumulative mortality after intravenous infection 
(Table 13) . 
The successive low dose (80 ~g/kg) followed by 
high dose (400 ~g/kg) drug regimen has been proven to be 
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effective in reducing leg swelling in drug treated mice 
as compared to control animals (Figure 12, 15, 16) regard-
less of the inoculum size tested. In an experiment where 
drug was initially administered by gavage (Figure 13), 
followed by drinking water administration of SM-1213, 
significant differences in abscess sizes were also ob-
served between control and drug treated mice. Gavage 
therapy was discontinued due to the revelation that gavage 
therapy could cause alterations of immune responses as a 
result of the additional stress received during this 
procedure and due to the discovered rapid clearance of 
SM-1213 in the urine when administration was limited to 
a single, heavy dosage per day rather than small doses 
three to four times per day as received in drinking water 
therapy (personal communication, P. Gordon and J. Majde). 
While low doses of drug (80 ~g/kg) given early in 
infection enhanced clearance of Candida from the spleen 
after leg inoculation (Table 14) and reduced mortality 
in intravenous studies (Table 13), larger doses (400 
~g/kg) effected a reduction in leg swelling relative to 
controls (Figure 12, 15, 16), while generating neither 
an increase nor a decrease in the number of recoverable 
Candida obtained within the abscesses (Figure 18). This 
suggests that larger doses of SM-1213 are anti-inflam-
matory, since smaller abscesses apparently contained a 
similar number of Candida organisms. 
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This has been borne out subsequently by experiments 
conducted by colleagues in this laboratory. In studies 
employing peritoneal exudate cells from SM-1213 treated 
mice, a biphasic dose response was noted. Twenty-four 
hours prior to cell harvest, either 10 7 Candida cells or 
20 mg of glycogen were injected into the peritoneum. In 
mice receiving 40 to 80 ~g SM-1213/kg doses for short 
duration (2 days) , a dose dependent increase in total 
leukocyte count and polymorphonuclear leukotaxis into the 
peritoneum was revealed. However, in mice receiving 800 
~g SM-1213/kg doses or greater for longer intervals (3 
to 60 days) , a dose dependent decrease occurred in PMN 
and leukocyte migration into the peritoneum. However, 
such a decrease was associated with an increase in micro-
bicidal abilities in the responding cells. 
Upon reinoculation of mice in the contralateral 
leg (Figure 14) , significant differences were obtained 
early after Candida injection between previously drug 
treated and control CBA/J mice. The appearance of smaller 
abscesses in the SM-1213 treated mice may be explained as 
the consequence of an enhanced immunity, since no further 
drug therapy was administered during the reinoculation 
interval. According to the work of Pearsall and Lagunoff 
(43), such protection would be indicative of an enhanced 
humoral response. However, these authors do not exclude 
the possible contribution of immune lymphocytes in the 
resolution of abscesses based on the available evidence. 
Further studies conducted by Pearsall et al (45) have 
demonstrated a direct anti-fungal activity of lymphokine 
preparations in vitro and suggest that the decrease in 
fungi in the leg lesions after the second week of the 
primary infection in vivo may be partly due to the con-
tribution of lymphocytes present in the lesions. 
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Little or no systemic spreading of Candida occurred 
in those studies where 7 X 10 6 Candida cells were injected 
intramuscularly. For the examination of immune mechanisms 
in convalescing mice, such a limited, localized lesion 
should prove ideal. In addition, since this inoculum 
gives reproducibly significant differences in abscess 
size between control and drug treated mice (Figure 15) , 
future studies examining the relationship of abscess size 
to candidal cfu per abscess should utilize this inoculum. 
While abscess sizes were reduced in drug treated 
mice inoculated with 1.25 X 10 7 C. albicans (Figure 16), 
no reduction in Candida count was observed on sacrifice 
days as determined by tissue homogenization procedures. 
However, no sacrifice days occurred on days of significant 
abscess size differences. It is unlikely that an erratic 
clearance of Candida would occur within the abscesses and 
it is more probable that a steady, progressive clearance 
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would occur as indicated in Figure 18. The frequency of 
candidal occurrence, as well as the total number of re-
coverable Candida,was similar in both the control and 
drug treated groups on days of sacrifice. 
Apparently, on days where no significant difference 
in abscess sizes was observed, a direct correlation ex-
isted between abscess size and the number of Candida cfu 
per abscess. However, few data points were used to deter-
mine this correlation and a greater number of points 
should be obtained for analysis before this relationship 
can be stated unequivocally. Also, points occurring 
where significant differences are present between control 
and drug treated abscess sizes must be analyzed in the 
future. 
A strikingly significant difference in the fre-
quency of Candida obtained from the kidneys of mice in 
these studies was obtained, whether culturing or tissue 
homogenization techniques were employed. Such differences 
are related to an enhanced clearance of Candida from the 
kidneys of drug treated mice, since no difference in 
candidal frequency was observed until day 18 post-
infection (Table 16). In addition, the total number of 
Candida present, as well as the frequency of occurrence, 
was greater in the kidneys of control mice (Figure 17). 
Current studies by colleagues in this laboratory 
have suggested a role for SM-1213 as a mitogenic agent. 
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Peritoneal exudate cells from mice treated with SM-1213 
have shown a significantly greater uptake of radioactive 
thymidine relative to controls, especially in the presence 
of phagocytic activity. 
The effect of SM-1213 on the reduction of extra-
cellular active oxygen production suggests an explanation 
for its ability to promote mitogenicity. The production 
of active oxygens by PMN leukocytes normally accompanies 
the process of phagocytosis as a result of an increase in 
the oxidative metabolism of these cells upon contact with 
a stimulus such as Candida albicans or zymosan (65). In 
mouse peritoneal cells which demonstrate chemiluminescence 
accompanying the phagocytosis of heat-killed Candida, 
prior in vivo SM-1213 treatment served to protect peri-
toneal phagocytes and lymphocytes from damage by reducing 
extracellular active oxygens in vitro. 
Damage to lymphocytes and phagocytes by active 
oxygens has been discussed by other researchers (8,54). 
Damage to fixed tissue also accompanies the production 
of active oxygens by stimulated neutrophils (53) and by 
active oxygens associated with an arthritic response (25). 
It may be that SM-1213 protects both fixed tissues 
and lymphocytes participating in an inflammatory response 
indirectly by reducing the release of active oxygens from 
neighboring polymorphonuclear leukocytes. Lymphocyte 
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mitogenicity could therefore be preserved in these pro-
tected cells due to the indirect influence of SM-1213. 
Thus, SM-1213 treatment reduces lymphoid cell damage at 
the site of inflammation in vivo, thereby preserving 
lymphocyte mitogenicity in vitro and therefore presumably 
in vivo. Such preservation could allow for the enhanced 
clearance of Candida from the kidney of mice treated with 
SM-1213, as demonstrated in Figure 17 and Table 17. 
In light of the possible mitogenic effect SM-1213 
may exert upon lymphocytic cells, as well as its ability 
to activate macrophages in tissue culture, a cellular 
role is also indicated in the enhanced clearance of 
Candida from the kidney in SM-1213 treated mice. Although 
histological sections of the kidney from mice injected 
with 1.25 X 10 7 Candida cells intramuscularly showed 
predominantly PMN leukocytes present, no sections were 
made after the second week of infection. Therefore, if 
a greater accumulation of mononuclear cells were to occur 
after the second week of infection [as in the abscess 
model proposed by Pearsall (44) ], such an accumulation 
may not have been detected. However, a small number of 
mononuclear cells were present in the kidney and at the 
site of abscess formation as observed by this researcher 
and by others (44). 
Cellular as well as humoral factors have also been 
suggested for the clearance of systemically spread Candida 
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from the kidneys after intravenous injection. Corbel and 
Eades (9) examined the relative susceptibility of CBA and 
New Zealand Black (NZB) mice, a strain known to spontan-
eously develop deficiencies in cell-mediated immune 
function (24) to systemic candidiasis. Six weeks after 
intravenous injection of Candida, CBA mice developed pre-
dominantly mononuclear reactions with lymphocytes and 
plasma cells readily apparent in the kidneys, while NZB 
mice developed progressive, disseminated infection with 
essentially non-specific PMN leukocytes and mononuclear 
phagocytes but no lymphocytes present in the kidneys. 
The greater susceptibility of NZB mice to Candida spread 
was suggested to be due to reduced ability to mount a 
specific T-lymphocyte dependent response to the fungus. 
Rogers and Balish (51) have suggested that humoral 
factors may be involved in the clearance of Candida from 
the kidneys of mice. Histological studies conducted by 
these authors have indicated that, for the first 21 days 
after infection, the predominant cell type was the PMN 
leukocyte. Few PMN's were observed at day 7 post-
infection; by day 14, however, a dramatic increase in the 
number of PMN's present occurred with the appearance of 
a few monocytes and almost no lymphocytes. By day 21, 
PMN's still predominated, and a small number of monocytes 
and lymphocytes were present. It was suggested that, if 
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the PHN leukocyte was responsible for the eventual clear-
ance of Candida from the kidney, the possibility of 
antibody-mediated protection by antibody plus complement 
mediated chemotaxis of PMN cells would be consistent with 
the observed data. However, the possibility of direct 
lymphokine mediated Candida clearance (45,56), as well as 
the influence of thymus derived cells upon the function 
of the P~~ itself (7,49), was also suggested. Winbald 
(66) and Hurley and Winner (26) also suggested a role for 
the PMN leukocyte early in murine kidney infection (prior 
to day 6 post-infection) . 
Finally, in histological studies conducted by 
Miyake et al (40), irradiated mice, with decreased phago-
cytic function, exhibited large numbers of mycelial 
Candida in kidney sections with little cellular infiltrate 
present two days post-intravenous infection. Normal or 
nude mice with unimpaired phagocytic function showed 
little Candida present in the kidneys. Non-immune phago-
cytosis is therefore important early in infection. 
By 20 days post-infection, normal mice exhibited 
a large cellular infiltrate with an accumulation of macro-
phages and little or no Candida was observed. In nude 
mice, however, little cellular infiltrate was present, 
while large numbers of Candida occurred in the kidney 
pelvis. 
Thus, non-immune phagocytosis confines Candida 
early in infection, while, at day 20 with the contribu-
tions of cellular and humoral elements, Candida can be 
cleared from the kidney. 
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SUMMARY 
SM-1213, a substituted monosaccharide with irnrnuno-
modulatory activity, was examined for its effects on 
pathogenesis and immunity in experimentally induced 
Candida albicans infections in laboratory animals and for 
its effects on the intracellular germ tube elongation and 
viability of Candida in tissue culture. 
In vitro studies utilizing non-immune guinea pig 
pe~itoneal Pi~ and macrophages indicated that the glycogen 
induced PMN leukocyte was better able to suppress the 
intracellular germ tube elongation of Candida albicans 
than was the oil induced macrophage. The addition of 
whole, normal guinea pig serum to the tissue cultures 
reduced the average germ tube length of the oil induced 
control sample significantly. The drug treated samples 
were not significantly affected by the addition of serum. 
It was speculated that SM-1213 was mimicking a serum 
factor important to the macrophage for its inhibition of 
germ tube elongation. In glycogen induced celis, the 
addition of serum to the tissue culture medium increased 
the number of Candida remaining in the yeast form. This 
factor may play an important role in limiting the spread 
of Candida attributed to the formation of invasive, hyphal 
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forms. The addition of SM-1213 reduced both the average 
germ tube length of intracellular Candida and the per-
centage of viable cells remaining after phagocytosis. 
This effect was particularly significant at the 0.001 
~g/ml dose level. 
In order to determine the effects of SM-1213 on 
parameters of host defense against systemic candidal 
infection, experiments were conducted on mice infected 
intravenously with Candida albicans. In systemically 
infected Ha/ICR mice, SM-1213 could reduce cumulative 
mortality when administered for specific 24-hour intervals 
in the drinking water. A dosage of 80 ~g/kg/day was 
highly effective when administered from day 3 to 4 in 
infection and was less effective when given earlier. 
This suggests that immune mechanisms may be most sensitive 
to regulation three days post-infection and that treatment 
prior to infection is unnecessary, unlike other immune-
potentiating drugs. 
An injection of 1.25 X 10 7 Candida albicans cells 
into the leg muscle of CBA/J mice gave a consistent, self-
limiting lesion which could be easily measured and which 
served as an indicator of the pathogenesis of infection. 
Histopathology conducted here and by others has indicated 
that resistance to infection involves the early mobiliza-
tion of non-immune phagocytes in both the kidney and the 
abscess. The predominant cell produced early after in-
fection was the PMN, which has been shown in vitro to be 
an effective inhibitor of candidal spread. 
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Under proper drug protocols, consisting of succes-
sive doses of low (80 ~g/kg/day) followed by high dose 
(400 ~g/kg/day) treatment, significant differences in 
abscess sizes between the drug and control groups were 
observed early after infection (day 5 to 8). If non-
immune phagocytes are the primary cell type present early 
in infection, SM-1213 can reduce inflammation produced by 
such cells when administered in this manner. The number 
of Candida recovered from the abscesses of drug and con-
trol groups were not significantly different on days of 
sacrifice. Therefore, while SM-1213 reduces inflammation, 
it does so without impairing net fungicidal capabilities 
of the responding leukocytes. 
The possible anti-inflammatory effect of SM-1213 
may serve to protect proto-immune cells from inflammatory 
injury so that, when cellular factors are mobilized later 
in infection, fungal clearance is more rapid and complete. 
Humoral factors may also play an important role in kidney 
as well as abscess pathology. Protection of cutaneously 
immunized mice upon subsequent intravenous challenge has 
been attributed to a predominantly humoral response. 
Antibody-mediated transfer of immunity against leg lesion 
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development has been demonstrated by others and a possible 
direct candidacidal effect due to lymphokine production 
has been proposed. The mechanism of Candida clearance 
from the kidneys of systemically infected mice has been 
the subject of much controversy; however, early mobiliza-
tion of non-immune phagocytes followed by subsequent T-cell 
mediated immunity appear to be important factors. 
When larger doses of Candida were used as leg 
inocula (1.25 X 10 8 ), the greatest differences in abscess 
sizes between drug and control groups occurred late in 
infection. If clearance of Candida from the abscesses 
late in infection is due to cellular elements (lymphokine 
production in particular), SM-1213 could also reduce 
inflammation caused by this system late in infection. 
Upon reinoculation of recovered mice, animals which had 
been treated with SM-1213 during the course of the primary 
infection produced smaller abscesses than did the control 
group. Therefore, SM-1213 enhanced the development of 
immunity to a second infection without additional drug 
treatment. In addition, the more complete clearance of 
Candida from the spleen in drug treated mice also suggests 
an enhancement of immune mechanisms without an enhancement 
of inflammation. The mitogenicity of SM-1213 would sup-
port an opsonin or cellular immune promoted enhanced 
clearance of Candida from the kidneys. 
138 
Finally, when an inoculum of 7 X 10 6 Candida cells 
was injected intramuscularly into mice, a more localized, 
limited lesion occurred with little or no systemic 
spreading of Candida. This suggested that, if an inoc-
ulum was small, non-immune phagocytosis was able to limit 
the spread of Candida early in infection more efficiently 
than when larger inocula were used. Abscesses produced 
as a result of the lower inoculum were smaller and re-
gressed earlier after infection. Highly significant 
differences were observed in abscess sizes between con-
trol and drug treated groups when successive low and high 
drug doses were administered. 
In conclusion, the above studies, along with those 
of others, have demonstrated that SM-1213 can enhance the 
host's ability to produce an anti-candidal effect which 
may be facilitated by an indirect, anti-inflammatory 
action. 
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